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Chapter I  
 
LITERATURE STUDY 
 
 
Partially published in Quaegebeur A and Carmeliet P. Oxygen sensing: a 
common crossroad in cancer and neurodegeneration. Curr Topics Microbiol 
Immunol 345, 71-103 (2010). 
 
1 INTRODUCTION: AND THEN THERE WAS OXYGEN… 
Since the appearance of oxygen in the atmosphere more than 2 billion years 
ago, eukaryotic life has become critically dependent on aerobic metabolism 
(Semenza 2007). Since then, molecular oxygen (O2) serves as terminal 
electron acceptor in a process referred to as oxidative phosphorylation, 
providing the cell with a highly efficient means of energy production. 
However, given the reactive nature of oxygen, mitochondrial oxidative 
metabolism also exposes the cell to the threat of reactive oxygen species 
(ROS). Both decreased oxygen levels (hypoxia) and oxidative stress, resulting 
from excessive ROS generation, posed some of the greatest evolutionary 
challenges for aerobic life (Taylor and Pouyssegur 2007). Therefore, it is not 
surprising that organisms have developed a variety of oxygen sensing and 
adaptive systems, allowing a tightly regulated oxygen homeostasis. 
One of these oxygen sensing mechanisms is provided by the family of 
the prolyl hydroxylase domain proteins. In conditions of low oxygen 
availability, they will activate various protective responses that serve to 
restore the oxygen homeostasis. This evolutionary conserved adaptive 
program has received great medical attention in recent years as hypoxia-
related stress and deregulated oxygen homeostasis are commonly implicated 
in acute insults (e.g. ischemia of organs) as well as chronic disease states 
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(e.g. cancer, neurodegeneration and inflammation) (Quaegebeur and 
Carmeliet 2010).  
During this doctoral thesis, I focused on the role of these prolyl 
hydroxylase domain proteins in brain ischemia with specific attention to the 
question whether and how effects on neuronal metabolism could confer 
neuroprotection.  As an introduction to the data obtained during this doctoral 
work, I will first give an overview of the described functions of the PHDs. Next, 
I will review why the brain is so vulnerable to ischemia, discussing the knowns 
and the unknowns of brain metabolism. Then, I will introduce ischemic stroke 
and neurodegenerative disorders as two examples of disturbed oxygen 
homeostasis. Finally, I will elaborate on the hypothesis that inhibition of PHDs 
would be beneficial in these brain diseases.  
 
 
2 PROLYL HYDROXYLASE DOMAIN PROTEINS: A FAMILY OF OXYGEN 
SENSORS 
 
2.1 The Physiology of Oxygen Sensing 
For aerobic energy generation, cells are dependent on a regular oxygen 
supply. Vitally important for maintaining metabolic homeostasis in a cell is that 
oxygen consumption and delivery are in balance. However, discrepancies 
between oxygen delivery and demand are common, not only in diverse 
disease states (e.g. ischemia and cancer). Also in physiological conditions, 
cells are often exposed to fluctuations in oxygen levels (e.g. upon physical 
exercise). When oxygen consumption exceeds supply, cellular oxygen levels 
will drop and hypoxia arises. This will abruptly threaten the energetic balance, 
resulting in potentially life-threatening damage of an organ or tissue. Aerobic 
species have therefore developed various oxygen sensing mechanisms during 
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evolution, both at the cellular and systemic level, as a protection against these 
conditions of insufficient oxygen supply (Quaegebeur and Carmeliet 2010). 
At the systemic level, chemoreceptors in the carotid and aortic bodies 
signal changes in oxygen, CO2 and pH levels to cardiorespiratory centers in 
the central nervous system (Taylor et al 1999). These will adapt respiration, 
heart rate and blood pressure to ensure adequate oxygenation of the blood 
and sufficient perfusion. Another homeostatic mechanism acting at the 
systemic level is the production of erythropoietin (EPO) in the kidney, 
triggered by systemic hypoxia. EPO will stimulate erythrocyte production and 
in this way enhance the oxygen carrying capacities of the blood (Jelkmann 
2011).  
Oxygen sensing at the cellular level is mainly orchestrated by the prolyl 
hydroxylase domain proteins (Kaelin and Ratcliffe 2008), which were the focus 
of this doctoral thesis. This family of prolyl hydroxylase domain proteins 
activate in an oxygen-dependent manner a major transcriptional pathway 
governed by the hypoxia-inducible factors, allowing the cell to transduce 
oxygen levels to adaptive gene expression. 
 
2.2  Prolyl Hydroxylase Domain proteins: the molecular players of 
cellular oxygen sensing 
The Prolyl Hydroxylase Domain proteins, or shortly PHDs, belong to a family 
of 2-oxoglutarate dependent iron(ii)-dioxygenases. PHDs are enzymes that 
hydroxylate different target proteins at specific proline residues. PHDs act as 
bona fide oxygen sensors because they use molecular oxygen as a substrate 
in their hydroxylation reaction (Aragones et al 2009, Kaelin and Ratcliffe 2008, 
Quaegebeur and Carmeliet 2010, Schneider et al 2009). Mammalian cells 
possess three different PHD isoforms (PHD1-3). 
The best-known hydroxylation targets of the PHDs are the hypoxia-
inducible factors (HIFs). This transcription factor family acts as a master 
regulator of oxygen homeostasis by engaging an adaptive transcriptional 
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response. More than 20 years ago, EPO was discovered as the first gene 
regulated by HIF (Semenza and Wang 1992). To date, this HIF family is 
believed to control the expression of possibly more than 1000 genes 
(Semenza 2014). HIF is a heterodimer, composed of an oxygen-labile HIF-α 
subunit and constitutive HIF-β subunit. In mammals, HIF-α exists as 3 
isoforms (HIF-1α, -2α and -3α) of which HIF-1α and HIF-2α are best 
characterized (Majmundar et al 2010).   
When oxygen is sufficiently present, PHDs hydroxylate two proline 
residues of HIF-α (pro402 and pro564) located on the oxygen-degradation 
domain of HIF-α. The Von Hippel Lindau (VHL) protein will recognize this 
posttranslational modification and will recruit an E3 ubiquitin ligase complex 
that via ubiquitination will target HIF-α for proteasomal degradation (Kaelin 
and Ratcliffe 2008, Schofield and Ratcliffe 2004). In other words, in normoxic 
conditions, PHDs’ hydroxylation activity keeps HIF-α levels low (Figure 1). 
Indeed, in normoxia, HIF-α has a half-life of less than 5 minutes (Berra et al 
2001, Huang et al 1998). Consequently, when oxygen levels drop, PHDs lose 
their activity and HIF-α will no longer be degraded. The accumulating HIF-α 
will form a complex with its constitutively expressed counterpart HIF-β (also 
known as the aryl hydrocarbon receptor nuclear translocator) and bind to the 
hypoxia-responsive element (HRE) in the promotor of numerous genes (Figure 
1). This transcriptional response can affect a broad range of biological 
processes but most importantly, it will affect the vasculature and cellular 
metabolism. By increasing the expression of angiogenic factors such as 
vascular endothelial growth factor (VEGF), oxygen supply will be promoted, 
while cellular metabolism will be adapted to reduced oxygen levels, for 
instance by increasing the expression of pyruvate dehydrogenase kinase 
(PDK), thereby inhibiting the mitochondrial respiration (Quaegebeur and 
Carmeliet 2010). In the next paragraph, I will elaborate further on how PHDs 
regulate this metabolic homeostasis and more specifically, how their 
biological and catalytic properties allow them to both sense and instruct 
changes in vascular supply and cellular metabolism. 
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Figure 1: PHDs regulate HIF-α stability in an oxygen-dependent manner  
In normoxia, PHDs will hydroxylate HIF-α. This hydroxylation reaction will lead 
to the recruitment of Von-Hippel-Lindau (VHL) and E3 ubiquitin ligase (E3) that 
via ubiquitination will target HIF-α for proteasomal degradation. In hypoxia, 
PHDs lose their activity, allowing the HIF-α subunit to dimerize with the 
constitutive HIF-β subunit. Via binding to the hypoxia-responsive element 
(HRE), this complex of transcription factors will stimulate gene expression 
with the purpose of restoring the oxygen homeostasis.  Vegf: vascular 
endothelial growth factor; Pdk1: pyruvate dehydrogenase kinase 1. 
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2.3  Vessels and metabolism: the IN- and OUTPUT of PHDs 
The nature of stimuli to which PHDs respond and the biological processes 
regulated by PHDs, make PHDs the paramount orchestrators of a tight 
oxygen and metabolic homeostasis. Indeed, they feed back to processes that 
influenced their activity in the first place.  
 
2.3.1. INPUT – TO WHICH FACTORS DOES PHD ACTIVITY RESPOND?  
As outlined earlier, oxygen levels dictate PHD activity. However, not only 
oxygen, but also 2-oxoglutarate is required for the proline-hydroxylation 
function, as well as a ferrous iron molecule (Fe2+) in the catalytic core of the 
PHDs (Quaegebeur and Carmeliet 2010). Therefore, PHDs have a function 
that goes beyond oxygen sensing strictu sensu, as they are sensitive to 
various metabolic signals (Figure 2). Hence, the catalytic properties of the 
PHDs are most elegantly designed to allow them orchestrating this complex 
metabolic equilibrium. 
 
a. Oxygen 
PHD activity responds to oxygen levels, as molecular oxygen is required 
as a substrate in the hydroxylation reaction. Hypoxia arises when the 
oxygen supply does not meet the oxygen demand and results in a drop in 
ATP production. This occurs during embryogenesis (when the embryo 
becomes too large to rely on simple oxygen diffusion) or in the context of 
various diseases such as infarctions (when an occluded blood vessel 
acutely deprives tissue from oxygenation) and cancers (when malignant 
cells outgrow their own vasculature). The rather low affinity of PHDs to 
oxygen (Km of 100-250 mM) allows PHDs to act dynamically in the 
physiological oxygenation range (Ehrismann et al 2007, Koivunen et al 
2004). This implies that small alterations in oxygenation will result in 
substantial effects on PHD activity and that PHDs will already initiate an 
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adaptive response before oxygen tension will drop too far to maintain 
mitochondrial respiration.  
 
b. Tricarboxylic acid (TCA) cycle metabolites  
Besides oxygen, the levels of TCA cycle metabolite 2-oxoglutarate (α-
ketoglutarate) will also affect PHDs’ activity because α-ketoglutarate 
undergoes oxidative decarboxylation to succinate during the 
hydroxylation reaction (Epstein et al 2001). This mechanism most likely 
explains why drugs showing structural analogy with 2-oxoglutarate (e.g. 
dimethyloxalylglycine (DMOG)) as well as amino acid starvation inhibit 
PHD function due to competitive inhibition with and depletion of 2-
oxoglutarate respectively (Duran et al 2013, Fraisl et al 2009). This 
metabolic regulation is also exemplified by the PHD-HIF pathway 
activation in malignant tumors based on loss-of-function mutations in 
fumarate dehydrogenase and succinate dehydrogenase (Isaacs et al 
2005, Selak et al 2005). The accumulation of fumarate and succinate 
respectively, is believed to inhibit PHDs via product inhibition. Conversely, 
the R-enantiomer of oncometabolite 2-hydroxyglutarate, accumulating in 
gliomas due to isocitrate dehydrogenase (IDH) mutations, was recently 
shown to activate PHDs (Koivunen et al 2012).  
 
c. Redox state 
As shown in figure 2, PHD activity also requires iron in the catalytic site for 
its activity. This iron has to be reduced (Fe2+) in order to enable 
hydroxylation activity. This suggests that PHD activity would be sensitive 
to the redox state of a cell, since an excess of oxygen radicals would 
oxidize ferrous iron (Fe2+) to ferric iron (Fe3+) (Gerald et al 2004). Treatment 
of cells with anti-oxidants (e.g. ascorbate) indeed prevents HIF 
stabilization (Gerald et al 2004, Knowles et al 2003). However, it remains 
controversial to what extent redox state affects PHD activity in non-
hypoxic conditions. Of note, this mechanism also implies that iron 
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depletion (e.g. by iron chelating agents) will result in HIF accumulation via 
PHD inhibition (Epstein et al 2001). 
 
 
Figure 2: PHDs as paramount cellular integrators of different metabolic 
signals 
PHDs do not only need oxygen to carry out the hydroxylation reaction, both 
2-oxoglutarate and iron (Fe2+) are also used as cofactors. In red are the 
signals that will temper PHD activity. In green are the signals that will promote 
PHD activity. ROS: reactive oxygen species; R-2HG: R-enantiomer of 2-
hydroxyglutarate.  
 
2.3.2. OUTPUT: VASCULAR AND METABOLIC EFFECTS 
PHDs do not merely function as sensors of insufficient oxygen supply or 
metabolic imbalance. They will directly instruct adaptations in an attempt to 
re-establish the oxygen homeostasis. This hypoxic response involves a broad 
variety of biological processes – beyond vessels and metabolism – such as 
inflammation, autophagy, endoplasmatic reticulum stress, apoptosis, cell 
stem physiology etc. (Quaegebeur and Carmeliet 2010). With oxygen delivery 
and consumption as ultimate determinants of the hypoxia response, I will limit 
further discussion to the metabolic and vascular effects mediated by PHD 
HIF-α OHOH
HIF-α
O22-oxoglutarate
succinate + CO2
Fe2+R-2HG
succinate
fumarate
hypoxia
ROS
iron depletion
ascorbate
PHD
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inhibition. Essentially, PHD signaling will initiate programs that enhance 
oxygen supply via “cell extrinsic” mechanisms on the one hand, and that 
reduce energy expenditure and oxygen consumption via “cell intrinsic” 
mechanisms on the other hand (Figure 3). 
 
 
Figure 3: Vessels and metabolism: the messengers to and the actors of 
the PHDs  
Scheme on the main functions of the PHDs showing that, in hypoxia, reduced 
PHD activity will activate a variety of responses in order to safeguard the 
oxygen homeostasis. At the vascular level, angiogenesis, erythropoiesis and 
vessel perfusion will be promoted. Metabolic changes aim to enhance the 
cell’s resilience against hypoxia and ROS by decreasing its oxygen 
consumption, increasing glycolysis, reducing protein synthesis and promoting 
anti-oxidant activity. This scheme is a simplification as besides vessels and 
metabolism many other cellular processes (…) can be affected by PHDs. 
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a. EXTRINSIC mechanisms – OXYGEN SUPPLY 
As organisms grew larger over time in evolution, more complex and elaborate 
transport systems for oxygen delivery arose. During embryogenesis, the 
circulation is the first system to become functional (Semenza 2014). In adult 
organisms, the vascular network is dormant in health, but when a tissue is 
deprived of oxygen, it will induce a response designed to increase oxygen 
delivery by enhancing angiogenesis and erythropoiesis. Genetic mouse 
studies demonstrated that PHDs participate in this adaptive response.   
 
i. erythropoiesis 
A role in erythropoiesis has been reported for several PHD isoforms, but most 
clearly for PHD2. Postnatal PHD2 deletion (Minamishima et al 2008, 
Minamishima et al 2009, Takeda et al 2008) as well as combined loss of PHD1 
and PHD3 (Takeda et al 2008) result in polycythemia due to increased renal 
EPO production. The discovery of heterozygous mutations in the PHD2 gene 
in patients with idiopathic erythrocytosis underscores the relevance of PHDs 
in erythropoiesis in humans (Percy et al 2006). In addition, combined loss of 
PHD1, PHD3 and hepatic PHD2 reactivates hepatic EPO production 
(Minamishima and Kaelin 2010). Not surprisingly, clinical trials with PHD 
inhibitors are currently running to treat anemia due to kidney failure. 
 
ii. angiogenesis 
Effects on angiogenesis seem so far to be exclusively linked to PHD2. 
Postnatal disruption of PHD2 increases blood vessels in different organs 
(Takeda et al 2007) resulting in dilated cardiomyopathy and circulatory 
congestion (Minamishima et al 2008). The effects of PHD2 deficiency on the 
vasculature seem to be dependent on the residual PHD2 activity and the 
context. Indeed, heterozygous deletion of PHD2 was shown to normalize 
tumor vessels, thereby improving perfusion and chemotherapy delivery to the 
tumor (Leite de Oliveira et al 2012, Mazzone et al 2009), as well as to 
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stimulate collateral artery growth, governing protection against limb ischemia 
(Takeda et al 2011). Interestingly, the downstream effectors of PHD2 can vary 
depending on the organ and context. Whereas partial PHD2 deficiency in 
endothelial cells instructed tumor vessel normalization via HIF-2α (Mazzone et 
al 2009), the angiogenic response in postnatally PHD2-deficient mice was 
more likely to be HIF-1α-dependent (Takeda et al 2007) and the increased 
arteriogenesis in limbs of heterozygous PHD2 deficient mice was HIF-
independent (see below) (Takeda et al 2011).  
 
b. INTRINSIC mechanisms – CELLULAR METABOLISM 
 
i. Introduction on cellular metabolism 
Cellular metabolism can be defined as the set of chemical reactions within a 
cell. One of the main functions of cellular metabolism is to generate energy 
that cells use to fuel various processes such as protein synthesis, organelle 
turnover, ion homeostasis and many others. In almost any mammalian cell 
type, glucose is a major source for ATP production. Upon entering the cell, 
glucose will be converted into pyruvate in a process that is referred to as 
“glycolysis”. Essentially, pyruvate has two major fates. Pyruvate can be 
metabolized to lactate, which will be transported outside of the cell. This 
process is known as “anaerobic glycolysis” or “fermentation” and generates 2 
molecules of ATP per molecule of glucose.  
Alternatively, pyruvate will enter the mitochondria and via different 
oxidation steps in the TCA cycle give rise to nicotinamide adenine 
dinucleotide (NADH) molecules, which serve as electron donor for the electron 
transport chain (ETC). Here, electrons are passed along a chain of redox 
complexes, enabling a proton gradient to be built up across the mitochondrial 
membrane, necessary for ATP production. Oxygen is the final electron 
acceptor at the end of the ETC. Oxidation of one glucose molecule yields 36 
molecules of ATP, which leaves this process of “oxidative phosphorylation” 
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the more efficient way of generating energy in normoxic conditions (Figure 4) 
(Berg 2007). As an obligatory byproduct of oxidative phosphorylation, 
superoxide radicals will be generated when electrons escape the ETC 
prematurely and react with oxygen molecules.  
 
 
Figure 4: The basics of cellular glucose metabolism. 
Glycolysis refers to the stepwise conversion of glucose into pyruvate. 
Pyruvate can either be converted to lactate or enter the mitochondria where it 
undergoes different oxidation steps in the TCA cycle. Electron transfer along 
the complexes of the electron transport chain will result in ATP production 
and O2 consumption. As a normal byproduct of this process of oxidative 
phosphorylation (OXPHOS), limited amounts of superoxide radicals (ROS) will 
be generated. Note: glycolysis generates low amounts of ATP, but allows 
energy production in hypoxia, whereas the process of mitochondrial 
respiration is a more efficient way of energy generation. For reasons of 
simplicity and clarity, the stoichiometry of the reactions has been omitted. 
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ii. The role of HIF-α in hypoxic metabolism 
When oxygen supply becomes limiting, cellular oxygen levels will drop to a 
level where the electron transport through the ETC (and consequently, ATP 
production) can no longer meet the ATP demand. This hypoxic event will have 
two major metabolic consequences: first, the acute drop in ATP production 
will lead to an energetic crisis, jeopardizing all the energy-consuming cellular 
processes. Second, and somewhat counter intuitively, hypoxia results in a 
surge in mitochondrial ROS generation (Chandel et al 2000). Increased 
NADH/NAD+ ratio and reduction of electron carriers likely favor electron 
leakage and generation of superoxide radicals. Especially at complex I and III, 
electrons can escape and react with the limited oxygen molecules still 
present, generating excessive amounts of reactive oxygen species (ROS), 
threatening the structural and functional integrity of the cell (Bolanos et al 
2009).  
As a protective physiological response to this hypoxic stress, a cell will 
generally switch from aerobic metabolism to anaerobic glycolysis, an oxygen-
independent way of energy generation. In various papers, this hypoxia-
induced metabolic rewiring has been linked to HIF-1α activation (Schneider et 
al 2009). HIF-1α accumulation in hypoxia will regulate the following metabolic 
processes in order to protect the cell against metabolic demise (Figure 5):  
 
1) Reducing oxygen consumption (energy conservation) 
HIF-1α will shut down mitochondrial respiration in order to adjust the 
oxygen consumption to the lower oxygen levels. By inducing pyruvate 
dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase, 
HIF-1α will prevent the entry of pyruvate into the mitochondria (Kim et al 
2006, Papandreou et al 2006). Another way of HIF-1α lowering 
mitochondrial respiration is by downregulating the expression of 
succinate dehydrogenase subunit B (SDH-B) (Dahia et al 2005). HIF-1α 
will also lower mitochondrial content by stimulating mitophagy and 
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counteracting mitochondrial biogenesis (Zhang et al 2007, Zhang et al 
2008). At the same time, the residual respiration will become more 
efficient by a HIF-mediated switch from isoform Cox4.1 to Cox4.2 
(Fukuda et al 2007), where the latter has an improved affinity for oxygen.  
  
2) Increase of anaerobic glycolysis (energy compensation) 
In an attempt to generate sufficient ATP despite hypoxia, HIF-1α will 
promote the glycolytic flux. Hereto HIF-1α will upregulate the expression 
of several glycolytic genes: glucose transporter GLUT1, hexokinase, 
enolase, lactate dehydrogenase (LDH) etc. (Denko 2008). More recently, 
the M2 isoform of pyruvate kinase (PKM2), catalyzing the last step in 
glycolysis, was identified as a novel target of HIF-1α in cancer cells (Luo 
et al 2011). PKM2 is mainly expressed in proliferating cells and is less 
active than the PKM1 isoform (Vander Heiden et al 2010). It is believed 
that via accumulating glycolytic intermediates, PKM2 expression in 
cancer cells facilitates the generation of macromolecular precursors, 
necessary for biomass duplication.  
To prevent intracellular acidification, the accumulating lactate in 
the cell will undergo efflux via monocarboxylate transporters (MCTs) and 
the Na+/H+ exchanger 1 (NHE-1). The expression of these transporters is 
also driven by HIF-1α (Shimoda et al 2006, Ullah et al 2006). Hypoxia will 
also indirectly enable anaerobic glycolysis by promoting glycogen 
accumulation and utilization. Indeed, both glycogen synthase and 
glycogen phosphorylase, the enzymes responsible for glycogen synthesis 
and glycogen breakdown respectively, are induced in hypoxic conditions 
(Favaro et al 2012).  
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Figure 5: The canonical role of HIF-1α in hypoxic metabolism.  
In normoxia, most cells will generate ATP molecules predominantly via 
mitochondrial metabolism (orange), as this yields 15 fold more ATP molecules 
per molecule of glucose than glycolysis. In hypoxia, HIF-1α will a) lower 
mitochondrial respiration; b) increase glycolytic ATP production; and c) 
reduce energy expenditure.  
 
 
3) Reducing energy expenditure (oxygen conformance). 
In order to equalize energy need to the reduced energy generating 
potential, HIFs will shut down non-essential processes. For instance, HIF-
1α will inhibit overall protein synthesis via inhibition of the mammalian 
target of rapamycin (mTOR) pathway (Brugarolas et al 2004). Conversely, 
HIF is also able to stimulate biosynthesis especially in cells that continue 
their proliferation in hypoxia such as cancer cells. HIF-1α was found to 
stimulate the flux of glycolytic intermediates through the non-oxidative 
branch of the pentose-phosphate pathway, thereby generating ribose-5-
phosphate, which is used as a precursor for nucleotide synthesis (Zhao et 
al 2010). Additionally, HIF-1α was linked to reductive metabolism of 
glutamine in order to maintain fatty acid synthesis (Gameiro et al 2013, 
Metallo et al 2012, Mullen et al 2012). Lipid synthesis requires acetyl-CoA, 
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which becomes limiting in hypoxic conditions given the reduced entry of 
pyruvate into the mitochondria. Via stimulating the reductive carboxylation 
of α-ketoglutarate (originating from glutamine) to citrate, HIF-1α 
replenishes the acetyl-CoA pools. Different mechanisms have been 
proposed: in one study, HIF-1α was found to impair the activity of α-
ketoglutarate dehydrogenase (α-KGDH) via Siah2-mediated degradation 
of one of the subunits of α-KGDH (Sun et al 2014). Another study showed 
the necessity of ongoing α-KG oxidation in order to generate reducing 
equivalents for the reductive carboxylation (Mullen et al 2014). 
 
Many of these alterations have been shown to be HIF-1α-mediated, 
even though an additional role for HIF-2α is plausible. Nevertheless, it seems 
that HIF-1α and HIF-2α regulate rather distinct sets of metabolic genes. The 
role of HIF-2α in metabolism needs therefore further investigation (Majmundar 
et al 2010). The common interpretation of these HIF-mediated metabolic 
alterations is that they enable anaerobic energy generation. However, at O2 
levels of 1%, the oxygen tension in the mitochondria is not limiting for ATP 
production, triggering the question whether this drop in mitochondrial 
respiration would not serve redox rather than bioenergetics purposes by 
limiting the mitochondrial production of ROS (Semenza 2012). 
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iii. The role of PHDs in hypoxic metabolism 
1) PHD1 
Genetic studies in PHD deficient mice have shown that PHDs are involved in 
the metabolic switch from oxidative to glycolytic metabolism and hence act 
as key regulators of cellular metabolism. PHD1 is the isoform that has been 
most extensively linked to this hypoxic-metabolic shift. Both in muscle and 
liver, PHD1 deficiency reduced mitochondrial oxygen consumption through 
upregulation of PDK1 and PDK4 (Aragones et al 2008, Schneider et al 2009). 
As a consequence, mitochondrial ROS generation declined, attenuating 
oxidative damage of the mitochondria (Aragones et al 2008, Schneider et al 
2009). By preventing mitochondrial damage, PHD1-/-  muscle fibers were able 
to preserve a certain level of mitochondrial activity despite ischemia, whereas 
in wild type muscle fibers, extensive mitochondrial damage impeded 
respiratory activity, resulting in cell death (Figure 6).  
Even though no transcriptional changes were detected in glycolytic 
genes, PHD1-/- muscle fibers showed an enhanced glycolytic flux, likely as 
energy compensation (Figure 6) (Aragones et al 2008). Of importance, this 
metabolic switch from oxidative to glycolytic metabolism was observed in 
normoxic conditions as well, indicating that PHD1 deficiency acts via a 
preconditioning mechanism in the muscle and the liver: PHD1 deficiency 
prepares the tissue for a coming ischemic event by increasing its resilience 
against ischemia. The downside of this metabolic rewiring is that exercise 
endurance in these PHD1-/- mice was impaired as this relies on oxidative 
muscle metabolism (Aragones et al 2008). 
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Figure 6: Metabolic rewiring in PHD1 deficient muscle fibers  
Due to upregulation of PDK, PHD1 deficient muscle fibers reduce the entry of 
pyruvate into the mitochondria. As a consequence, oxygen consumption as 
well as mitochondrial ROS production ceases. Increased glycolytic flux and 
lactate excretion is likely to compensate for the reduced mitochondrial ATP 
production. In other words, PHD1 deficient muscle fibers show a shift from 
mitochondrial respiration towards glycolysis. For reasons of simplicity and 
clarity, the stoichiometry of the reactions has been omitted. 
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2) PHD2 
The role of PHD2 in cellular metabolism has been hardly described, but as the 
primary regulator of HIF-1α stability, one would assume that inactivation of 
PHD2 would induce via HIF-1α the above-described shift to anaerobic energy 
generation. Indeed, brains with a neuron-specific deletion of PHD2 showed 
enhanced levels of HIF-1α and glycolytic genes in hypoxic conditions (Kunze 
et al 2012). Also, somatic mutations in PHD2 have been associated with 
similar metabolic changes in cancer cells (Calvisi et al 2007, Kato et al 2006). 
Conversely, endothelial PHD2 deficiency indirectly reduced the HIF-1α-
induced metabolic changes in tumor cells showing decreased lactate and 
PDK levels. The lowered HIF-1α levels were the result of a HIF-2α-dependent 
vessel normalization and improved tumor oxygenation (Mazzone et al 2009). 
Furthermore, heterozygous PHD2 deficiency protected against the side-
toxicity of chemotherapy by mounting an anti-oxidant response (Leite de 
Oliveira et al 2012).  
 
3) PHD3 
A recent paper acknowledged a new role for PHD3 in metabolism. PHD3 was 
discovered to hydroxylate the glycolytic gene PKM2 (Luo et al 2011). When 
hydroxylated, PKM2 will via direct binding to HIF-1α in the nucleus, facilitate 
its transcriptional activity. As both PKM2 and PHD3 are HIF-1α targets, this 
modulation acts as a feed forward loop in stimulating glycolysis. The nuclear 
role of PKM2 as transcription modulator goes beyond HIF-1α binding, and 
needs further study.  
 
iv. Consequences for ischemic diseases 
The growing insights into PHDs’ major role in maintaining oxygen and 
metabolic homeostasis prompted scientists to investigate the implication of 
PHDs in ischemia tolerance and exploring PHD inhibition as a therapeutic 
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approach in ischemic diseases. Indeed, several studies over the last decade 
demonstrated that genetic deletion of one the PHD isoforms or 
pharmacological inhibition of all PHDs protects against ischemia in different 
organs. A selected list of studies reporting on hypoxic tolerant organs in mice 
with a genetic deletion of a specific PHD isoform is presented in table 1.  
 
 
Table 1: Role of PHDs in ischemic tolerance 
MOUSE ORGAN MECHANISM REFERENCE 
PHD1-/- muscle Reducing O2 consumption 
HIF-2α (>HIF-1α) 
(Aragones et al 
2008) 
 liver Reducing O2 consumption 
HIF-2α? 
(Schneider et 
al 2009) 
PHD2+/- muscle Increased collateral growth 
NF-κB 
(Takeda et al 
2011) 
PHD2 
hypomorph 
heart HIF? (Hyvarinen et 
al 2010) 
siRNA PHD2 heart Enhanced purinergic 
signaling 
HIF-1α 
(Eckle et al 
2008) 
cardiomyocyte 
specific PHD2-/-  
heart HIF-1α? (Holscher et al 
2011) 
 
Table overviewing a selection of reports, showing that PHD deficiency 
promotes ischemia tolerance. The genetic mouse model and the organ or 
tissue in which ischemia was induced is listed, as well as the mechanism of 
protection and its (putative) molecular mediator. 
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2.4  Complexity and diversity of the PHD-induced hypoxic 
response 
Given the broad range of oxygen concentrations between physiological 
oxygen levels and anoxia, the PHD-HIF cascade should allow a graded 
response. Also, as integrators of cellular homeostasis, PHDs should enable 
distinct responses adjusted to a variety of stimuli. To provide the necessary 
fine-tuning of the hypoxia response and shape a cellular outcome suited for 
the varying contexts of nature, severity and duration of the stimulus, the PHD-
HIF pathway exhibits a high degree of flexibility and complexity (Lendahl et al 
2009). This diversity is tailored at several levels: 
 
2.4.1 PHD1, 2 AND 3: THREE NON-REDUNDANT PHD ISOFORMS 
Worms and flies possess only one PHD isoform (referred to as Egln). This 
PHD isoform has in vertebrates, with a more advanced cardiorespiratory 
system, diverged into three different PHD isoforms (Taylor and McElwain 
2010). These three PHD isoforms have a homologous C-terminal catalytic 
domain, but show substantial differences in the N-terminal part. This adds a 
level of diversity to the hypoxic response in vertebrates as these three 
isoforms differ in tissue distribution, expression regulation, as well as their 
preferences for the different HIF-α isoforms. Indeed, genetic mouse studies 
have demonstrated that the three PHD isoforms are non-redundant and have 
diverging organ-specific functions. Table 2 shows a summary of some of the 
observed phenotypes in the different PHD knock-out mice.  
Factor inhibiting HIF (FIH) is another member of the same family of 2-
oxoglutarate dependent iron(ii)-dioxygenases. FIH hydroxylates in an oxygen-
dependent manner a specific aspargine residue on HIF-α that will impede the 
recruitment of ancillary transcriptional co-activators. This implicates that when 
FIH loses its activity in hypoxic conditions, HIF-α transcriptional activity will 
be facilitated (Quaegebeur and Carmeliet 2010). Since FIH exhibits a higher 
affinity for oxygen than PHDs, FIH will remain active at reduced oxygen 
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concentrations when PHDs have already lost their activity. In this way, FIH 
enables an additional fine-tuning of the hypoxic response (Schneider et al 
2009). 
 
Table 2 Different phenotypes in genetic knock-out mice of PHD1, 2 and 3.  
 
GENOTYPE PHENOTYPE 
PHD1-/- Protection against limb ischemia, yet increased muscle 
fatigue due to metabolic shift from mitochondrial respiration 
towards glycolysis in muscle (Aragones et al 2008) 
 Protection against ischemia-reperfusion injury in liver 
(Schneider et al 2009) 
 Reduced mammary gland proliferation due to decreased 
cyclin D1 levels (Zhang et al 2009) 
 Hyperplasia of pulmonary neuroepithelial bodies (Pan et al 
2012) 
 Protection against colitis due to reduced epithelial 
apoptosis and enhanced barrier function (Tambuwala et al 
2010) 
PHD2+/- Normal vascular development; tumor vessel normalization, 
leading to reduced metastasis and tumor invasiveness due 
to improved tumor oxygenation (Mazzone et al 2009) 
 Reduced cytotoxicity by chemotherapy in healthy tissue 
(Leite de Oliveira et al 2012) 
 Enhanced collateral network in limbs, governing protection 
against limb ischemia (Takeda et al 2011) 
PHD2-/- Congestive heart failure due to increased angiogenesis and 
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(postnatal) polycythemia (Minamishima et al 2008, Takeda et al 2007) 
PHD2-/- 
(prenatal) 
Embryonic lethality due to placental and heart defects 
(Takeda et al 2006) 
Cardiomyocyte 
PHD2 deletion 
Protection against acute myocardial ischemic injury 
(Holscher et al 2011) 
Adipocyte 
PHD2 deletion 
Protection against diet-induced obesity and improved 
glucose tolerance (Matsuura et al 2013) 
Epithelial 
PHD2 deletion 
Accelerated wound healing due to enhanced migration and 
proliferation of epithelium (Kalucka et al 2013) 
PHD3-/- Hypofunctional sympathoadrenal system and reduced 
blood pressure (Bishop et al 2008) 
 Enhanced innate immunity response and increased 
mortality in abdominal sepsis (Kiss et al 2012) 
 Reduced neutrophil inflammation in colitis (Walmsley et al 
2011) 
Hepatic 
PHD3 deletion 
Amelioration of diabetes mellitus due to increased insulin 
sensitivity (Taniguchi et al 2013) 
PHD1-/-PHD3-/- Viable and fertile with smaller litters and moderate 
erythrocytosis (Takeda et al 2007) 
PHD1-/-PHD2-/- 
postnatal 
Premature lethality due to hepatic steatosis and dilated 
cardiomyopathy (Minamishima et al 2009) 
PHD1-/-PHD3-/-
Hepatic 
PHD2 deletion 
Reactivation of hepatic EPO production (Minamishima and 
Kaelin 2010) 
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2.4.2 HIF-1α AND HIF-2α ARE NON-REDUNDANT TRANSCRIPTION FACTORS 
That HIF-1α and HIF-2α are non-redundant isoforms is illustrated by the 
embryonic lethality of both HIF-1α-/- and HIF-2α-/- mice (Majmundar et al 
2010). Whereas HIF-1α is expressed throughout the body, the distribution of 
HIF-2α and HIF-3α is more restricted to certain cell types in heart, lung and 
brain. How different HIF-α isoforms can induce distinct transcriptional 
responses is still subject of intense research. Yet, in general it is accepted 
that HIF-1α governs the classical hypoxic response whereas HIF-2α activates 
a more limited and specific set of genes and would rather be involved in the 
protection against oxidative stress (Majmundar et al 2010). HIF-3α is still very 
little studied and is assumed to act as a negative regulator of the HIF-
response. 
 
2.4.3 HIF-INDEPENDENT TARGETS: HYDROXYLATION AND NON-
HYDROXYLATION DEPENDENT 
Apart from HIF-α hydroxylation, HIF-independent protein targets of PHDs are 
increasingly being identified, among which members of the canonical nuclear 
factor kappa B (NF-κB) activation pathway (Chan et al 2009, Cummins et al 
2006, Xue et al 2010), activation transcription factor 4 (ATF4) (Hiwatashi et al 
2011, Koditz et al 2007), Forkhead box O3 (Foxo3a) (Zheng et al 2014) and 
others. Similarly to HIF-α regulation, these molecules will accumulate in 
hypoxia due to inhibition of their proteosomal degradation. In this way, PHDs 
do not only instruct the hypoxic adaptation, but convolute with biological 
responses beyond and intertwined with hypoxia such as inflammation, ER 
stress, etc. Notably, PHDs not necessarily rely on hydroxylation to affect their 
target proteins: growing evidence points to non-hydroxylation dependent 
effects of PHDs (Chan et al 2009, Xue et al 2010, Zhang et al 2009), even 
though the precise nature of these interactions remains obscure.  
 
	   25 
2.4.4 INTERACTION WITH OTHER SIGNALING CASCADES 
The PHD-HIF pathway has an intimate crosstalk with other major gene 
regulatory pathways, intersecting with diverse biological processes, such as 
with nutrient metabolism via regulation of 5' adenosine monophosphate-
activated protein kinase (AMPK), with protein synthesis, folding and 
degradation via effects on mTOR and the unfolded protein response (Wouters 
and Koritzinsky 2008), with apoptosis and cell survival via p53 (Xenaki et al 
2008), and many others. Finally, another level of complexity is added by the 
posttranslational modifications of HIF, as well as transcriptional regulation by 
microRNA and epigenetic factors (Lendahl et al 2009). 
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3 WHY SHOULD WE STUDY THE ROLE OF PHDS IN THE BRAIN? - 
FOOD FOR THOUGHT 
PHDs are key regulators of the hypoxic response and enable, via various 
mechanisms, cellular survival in conditions of insufficient oxygen availability. 
Still, the role of specific PHD isoforms and their mechanisms of action in 
different organs as well as their therapeutic potential warrant further 
investigation. This doctoral thesis aims to investigate the function and the 
therapeutic potential of the PHDs in the central nervous system. Do PHDs 
regulate the delicate oxygen and metabolic homeostasis of the brain? Would 
PHD inhibition be beneficial in conditions where this homeostasis is acutely or 
chronically disturbed? If so, via which mechanisms would PHD inhibition 
affect neuronal survival? And finally, is PHD inhibition a valid therapeutic 
target in neurological disease? 
 
Critical yet delicate oxygen and metabolic homeostasis in the BRAIN 
So far, our insights into the biological functions of PHDs in the brain have 
been rather scarce. Still, one can assume an important role for PHDs, as the 
brain is putatively the most sensitive organ to any metabolic disturbance. 
Indeed, in conditions of impaired oxygen or glucose supply such as in 
hypoglycemia or upon a drop in blood pressure, the brain will be the organ 
that suffers first and foremost. The brain’s tremendous metabolic 
requirements along with its rather limited reserve capacity is likely to explain 
this critical dependence on a continuous oxygen and glucose supply.  
 
3.1 The brain is an expensive organ: high oxygen and glucose 
consumption 
Even though the human brain makes up for 2% of the total body weight, it 
uses up to 20% of the total oxygen consumption in a resting body. This is 
mainly due to the extraordinary energy demands of normally functioning 
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neurons. The energetic cost of neurotransmission is high: electrical activity 
(which comprises restoration of the membrane potential following 
depolarization, ion pumping to maintain resting potential, synaptic transmitter 
and vesicle recycling) consumes up to 75% of the cerebral oxygen (Attwell 
and Laughlin 2001, Harris et al 2012) and will be impaired upon any 
interruption of oxygen supply (Astrup et al 1981, Hofmeijer and van Putten 
2012). Counterintuitively, with an oxygen pressure of only 1-5%, the brain has 
rather low oxygen levels compared to other systemic organs (Silver and 
Erecinska 1998).  
The high energetic cost of the brain is also reflected in its glucose 
consumption. The brain, even at rest, is responsible for 20% of total glucose 
consumption in the human body. In physiological conditions, glucose is the 
sole energy substrate for the brain (Mergenthaler et al 2013). 
 
3.2 Few defense mechanisms against ischemia 
Upon limited blood supply the brain will trigger mechanisms to safeguard 
cerebral perfusion. However, these act only in a narrow range. At the level of 
cellular metabolism, neurons have hardly any reserve capacity. 
 
3.2.1 VASCULAR RESPONSES TO SAFEGUARD CEREBRAL PERFUSION  
Using 20% of the cardiac output, the brain needs to maintain its perfusion 
within narrow ranges. One of the mechanisms that comes to play when blood 
pressure drops is cerebrovascular autoregulation: the brain will keep its 
perfusion constant within certain ranges of systemic blood pressure by 
adapting the vascular tone of pial and intraparenchymal arteries and arterioles 
(Aaslid et al 1989). Nevertheless, this protective mechanisms is exhausted 
rapidly and importantly, compromised in diseases such as diabetes mellitus, 
hypertension and after ischemic stroke (Jackman and Iadecola 2014).  
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In order to dynamically match blood supply to energy need, the brain 
possesses different neurovascular signaling mechanisms. Synaptic activity 
will evoke an increase in blood flow (functional hyperemia), via the release of 
vasoactive agents (Attwell et al 2010, Jackman and Iadecola 2014). At the 
capillary level, an intimate structural and functional interaction between 
endothelial cells, pericytes, glia and neurons – coined the blood-brain barrier 
(BBB) – allows for the regulation of microvascular flow, as well as to control 
the metabolic environment of the parenchym by limiting free molecular 
transport across this barrier, due to a tightly sealed endothelial layer (Iadecola 
2004, Iadecola and Nedergaard 2007, Zlokovic 2008). 
These mechanisms of neurovascular coupling are mechanisms that 
ensure adequate perfusion in physiological conditions, but are often 
compromised in common pathological conditions such as arterial 
hypertension and diabetes. This will pave the path for metabolic deregulation, 
which might ultimately progress to metabolic collapse and neuronal death 
(Iadecola 2004, Iadecola 2013, Jackman and Iadecola 2014)  
 
3.2.2 LITTLE METABOLIC RESERVE CAPACITY 
The reason why neurons are believed to be so vulnerable to ischemia is that 
they rely exclusively on oxidative metabolism for their energy production and 
are strictly glucose-dependent, yet are believed to have no internal energy 
stores such as glycogen (Mergenthaler et al 2013). In other words, they have 
to operate within a small margin of metabolic safety. 
Besides disrupting the energy balance, ischemia will also threaten the 
cellular redox status. Even though this highly oxidative cell produces large 
amounts of oxygen radicals during oxidative phosphorylation, neurons have 
proportionally little anti-oxidant defense mechanisms (Bolanos and Almeida 
2010). The high levels of redox-active metals (e.g. Fe2+) and polyunsaturated 
fatty acids together with the fact that neurons are postmitotic cells, which 
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accumulate DNA damage over time, are additional reasons for neurons to be 
so particularly prone to oxidative damage (Wang and Michaelis 2010).  
All of this is to be found in classical textbooks on brain metabolism. 
Meanwhile, a lot of these dogmas on bioenergetics have been rephrased or 
complicated with controversies. Given the extensive link between PHDs and 
metabolism, in the next paragraph, I will elaborate further on our current 
understanding of different metabolic pathways in neurons and their 
surrounding glial cells. 
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4  BRAIN METABOLISM: A COMPLEX PUZZLE WITH MISSING AND 
CONTROVERSIAL PIECES 
Notwithstanding the growing interest in brain metabolism, it remains fair to 
say that our current understanding of the role of distinct metabolic pathways 
in specific physiological (e.g. neuronal activation) and pathophysiological (e.g. 
ischemia) conditions is rather limited and at times even highly controversial. 
Whereas in the cancer field metabolic alterations have been extensively 
integrated with cellular signaling cascades during the last decade, these 
insights are only in its infancy in the field of brain metabolism. 
 
4.1 Bioenergetics in the brain  
“Glucose is the obligate energetic fuel for brain function” (Siesjo 1987). This 
longstanding dogma perfectly pictures the current controversies in the field. 
As a first clarification, this dogma implies blood-borne glucose. Neurons and 
their surrounding glial cells are believed to not only oxidize glucose, but also 
other mitochondrial substrates, such as glutamine/glutamate or lactate. 
However, all of these substrates are glucose-derived since the BBB is 
believed to only allow glucose to cross. Even this statement needs further 
refinement, as recently the contribution of lactate and ketone bodies in the 
blood to energy generation in the brain has been acknowledged, albeit only to 
a limited extent and in certain circumstances (i.e. physical exercise and 
prolonged fasting respectively) (Lutas and Yellen 2013, van Hall et al 2009). 
Another common knowledge in the field of brain metabolism is that 
neurons rely on oxidative metabolism for energy production. Indeed, being 
the cells with the highest energy requirements (Howarth et al 2012), they need 
the most efficient means of ATP production. Remarkably, neurons seem to be 
unable to upregulate their glycolytic flux to a similar extent as other cells 
would do in conditions of limited oxygen availability (Herrero-Mendez et al 
2009). Not surprisingly then that, next to cardiomyocytes, neurons are the 
cells with the highest oxygen consumption rate (De Bock et al 2013). This 
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oxygen consumption is tightly coupled to neural activity, corroborating the 
belief that synaptic activity is primarily fed by oxidative metabolism in 
neuronal mitochondria (Hall et al 2012, Harris et al 2012, Lin et al 2010, 
Rangaraju et al 2014). Nevertheless, glycolysis-derived ATP might be of 
physiological significance in some processes of neurotransmission such as 
fast axonal transport of neurotransmitter vesicles (Zala et al 2013), vesicular 
uptake of glutamate (Ikemoto et al 2003), and glutamate re-uptake 
(Schousboe et al 2010). Aerobic glycolysis was also postulated to fuel the 
biomolecular demand of neurons, even though this function is believed to 
become less important after postnatal brain development (Bauernfeind et al 
2014). Simplified and generally speaking, neurons need blood-born glucose 
and oxygen for energy production 
There is often a misconception about the substrates that can be 
utilized in neurons. The aforementioned dogma is commonly misinterpreted 
as if glucose would be the only substrate that can fuel mitochondria in 
neurons. However, it has become clear that neurons oxidize a substantial 
amount of other substrates besides glucose. Next to glucose, lactate and to a 
lesser extent glutamine are important fuels for neurons and both are believed 
to originate from astrocytic metabolism (Mergenthaler et al 2013, Zielke et al 
2009). This exchange of metabolites between astrocytes and neurons is 
imbedded in an intricate functional astrocytic-neuronal relationship in which 
astrocytes metabolically support their neighboring neurons in various ways 
(Belanger et al 2011). Not only energy substrates, but also neurotransmitters 
and glutathione precursors are being passed to neurons (Castro et al 2009, 
Dringen 2000). Being the cells that line the vessel wall, astrocytes take up 
glucose from the bloodstream and can store glucose as glycogen in order to 
build-up an energy back up (Brown and Ransom 2007, Brown and Ransom 
2014). As importantly, they will clear the synaptic cleft from accumulating 
glutamate after neuronal firing via glutamate re-uptake transporters (excitatory 
amino-acid transporters EAAT1 and EAAT2) (Bak et al 2006b). Two 
intercellular neuroglial metabolite exchange shuttles have been described 
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over the last decades: the lactate shuttle and the glutamate-glutamine cycle 
(Belanger et al 2011). However, ever since, the exact energy source for brain 
activation (glucose versus lactate) has been heavily debated, without any 
apparent consensus (Belanger et al 2011, Jolivet et al 2010, Mangia et al 
2011).  
On one side of the debate, there are the believers of the astrocytic-
neuronal lactate shuttle (ANLS). This metabolic theory was originally proposed 
two decades ago by Pellerin and Magistretti (Pellerin and Magistretti 1994) 
(figure 7). Their data suggested that lactate is the primary energy fuel for 
neuronal activity. According to their theory, glutamate released in the synaptic 
cleft following neuronal activation will be taken up by astrocytes and be 
transformed into glutamine. Since glutamate uptake as well as glutamine 
synthesis are ATP-dependent processes, glycolysis will rise in astrocytes. The 
resulting lactate will be released and be taken up by neurons to serve as an 
oxidative energy substrate (Belanger et al 2011). The astrocytes will also 
shuttle glutamine to the neurons, where it will be converted into glutamate 
(the glutamine-glutamate shuttle) (McKenna 2007). This does not only 
replenish their neurotransmitter pool, but also offers them an additional 
energy source for oxidation.  
Other groups strictly refute this compartmentalized view on brain 
metabolism based on different arguments. They claim that the predominant 
cellular fate of glucose during neuronal activation is neurons themselves 
(Mergenthaler et al 2013). In their views, blood-borne glucose is directly taken 
up by neurons via their high affinity GLUT-3 transporters (Simpson et al 2007), 
after which it is predominantly oxidized in the mitochondria (Bak et al 2006a, 
Hall et al 2012, Hertz et al 2007, Mangia et al 2011).  
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Figure 7: Astrocyte-neuron lactate shuttle 
Overview of metabolic pathways involved in the astrocyte-neuron lactate 
shuttle. Glucose is taken up from the blood in astrocytes via GLUT1 and in 
neurons via GLUT3. Glutamate (Glu) will after its release as neurotransmitter, 
be cleared from the synaptic cleft by the astrocytes via glutamate-uptake 
transporters (excitatory amino acid transporters, EAAT). Since this process is 
ATP-dependent, astrocytes will increase their glycolytic flux. According to the 
astrocyte-neuron lactate shuttle hypothesis, the resulting lactate molecules 
will be taken up by neurons via monocarboxylate transporters (MCT). Via 
conversion to pyruvate by lactate dehydrogenase (LDH), they can use lactate 
as an oxidative substrate in their mitochondria. The glutamate taken up in the 
astrocytes is believed to be recycled via conversion by glutamine synthetase 
(GS) into glutamine (Gln). Neurons will take up this glutamine and convert it by 
glutaminases (GLS) to glutamate, which can then be used again as a 
neurotransmitter (from Bélanger et al., Cell Metab 2011). For reasons of 
simplicity and clarity, the stoichiometry of the reactions has been omitted. 
 
These two conflicting perspectives also disagree on the fate of 
glutamate in astrocytes after re-uptake. Since stoichiometrically, the 
glutamate/glutamine cycle did not appear to occur in a one to one relationship 
(in which one molecule of glutamate is transformed into one molecule of 
glutamine in astrocytes), it is commonly believed that in astrocytes glutamate 
undergoes partial oxidative degradation as well as de novo synthesis (Bauer 
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et al 2012, Dienel 2013, Hertz et al 2007, McKenna 2007). Another level of 
controversy was added by two recent reports identifying oligodendrocytes 
(and not astrocytes) as lactate providers for neuronal axons (Funfschilling et al 
2012, Lee et al 2012). 
The supporters of the astrocytic-neuron lactate shuttle however, state 
that due to low expression of the aspartate-glutamate carrier in astrocytes, 
glutamate cannot enter the mitochondria and therefore cannot be oxidized 
(Berkich et al 2005, McKenna et al 2006, Pardo et al 2011). The resulting low 
malate-aspartate shuttle activity also prevents the mitochondrial oxidation of 
reducing equivalents NADH generated during glycolysis, making conversion 
to lactate necessary in order to replenish NAD+ (Belanger et al 2011).  
In conclusion, after several decades of research, the field of brain 
metabolism is still clouded by controversies and a general poor understanding 
on the contribution and regulation of different metabolic pathways. Different 
experimental and physiological circumstances are likely to explain some of 
the conflicting results. Combined approaches integrating 13C-labeled 
metabolic flux measurements with genetic mouse studies of metabolic genes 
will potentially shed more light on the many outstanding questions. 
 
4.2 Redox homeostasis in neurons 
4.2.1 MITOCHONDRIA AS MAIN SITE OF ROS GENERATION IN NEURONS  
The mitochondria are not only the bioenergetic engines of neurons; they also 
represent a major site of ROS generation. Electrons from reduced substrates 
are transferred from one redox-complex to another, building up a proton 
gradient across the mitochondrial membrane. At complex IV (cytochrome c 
oxidase), oxygen will serve as the final electron acceptor resulting in its 
reduction to water. Electrons can however escape prematurely, which 
commonly occurs at complex I and III (Andreyev et al 2005, Lambert and 
Brand 2004, Turrens 2003). An available oxygen molecule will trap this free 
electron, leading to the formation of a superoxide radical. More recently, 2-
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oxoglutarate dehydrogenase was also acknowledged as an important site of 
mitochondrial superoxide production (Starkov et al 2004, Tretter and Adam-
Vizi 2004). 
Under physiological conditions, superoxide radicals are continuously 
generated in low amounts as normal byproducts of oxidative phosphorylation 
(Barja 1999, St-Pierre et al 2002). There are however many factors that can 
influence the rate of superoxide production along the electron transport chain. 
From a simplistic point of view, one could reasonably guess that oxygen 
concentration is a determining factor. In extreme conditions this is indeed the 
case: in the absence of oxygen molecules, no superoxides will be formed. 
Still, oxygen availability will only be limiting when oxygen tensions drop below 
5 µM, which corresponds to almost anoxic conditions (Hoffman et al 2007). In 
addition, the redox state of the sites of superoxide generation and the 
mitochondrial membrane potential will also determine the likelihood of 
premature electron escape (Starkov and Fiskum 2003). In conditions of 
reduced ATP production and a low NAD+/NADH ratio, electrons will stall along 
the redox complexes and easily react with surrounding oxygen molecules. 
This explains why it is generally believed that hypoxia is associated with an 
increase in mitochondrial ROS formation (Bolanos et al 2009, Chandel and 
Schumacker 2000).  
Superoxides will immediately be neutralized by the abundant 
superoxide dismutase 2 (SOD2) enzyme in the mitochondria (Lin and Beal 
2006). The resulting hydrogen peroxide (H2O2) molecules need further 
detoxification as they can lead to the generation of highly reactive hydroxyl 
radicals and peroxynitrite, by metal-catalyzed reduction and interaction with 
nitric oxide (NO) respectively. When excessively present, these will oxidatively 
damage different biomolecules: oxidation and inactivation of redox-sensitive 
mitochondrial proteins (e.g. aconitase, complex I) will interfere with the 
mitochondrial bioenergetic function. Cumulatively, oxidative mitochondrial 
DNA strand breaks will disrupt transcription of mitochondrial proteins. Finally, 
peroxidation of lipids in the mitochondrial membrane will undermine its 
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structural integrity (Lin and Beal 2006, Starkov 2008). Thus, the mitochondria 
are not only the source of ROS but are at the same time also heavily under 
attack by it. This also illustrates how redox and bioenergetic dynamics are in 
an interactive fashion tied to the functional integrity of the mitochondria.  
Besides the mitochondria, other enzymes such as NADPH oxidase, 
xanthine oxidase and the cyclo-oxygenase pathway can result in ROS 
generation. However, the extent of their contribution to neuronal ROS 
generation is not yet fully understood and appears to be limited to specific 
pathological circumstances (Abramov et al 2007, Bolanos et al 2009).  
 
4.2.2 ROS SCAVENGING CAPACITY IN NEURONS  
As described above, there is a continuous production of ROS that need to be 
detoxified. Oxidative stress and the resulting damage arise when the 
antioxidant capacity can no longer meet the rate of ROS generation. Although 
literature on oxidative stress in brain disease is abundant, much less attention 
has been given to the regulation of antioxidant defense mechanisms. 
The role of superoxide dismutase (SOD) in transforming superoxide 
radicals to H2O2 was already mentioned. The two main enzymatic H2O2 
detoxification systems in neurons are catalase and glutathione peroxidase 
(GPx). Catalase will convert H2O2 to H2O and O2, whereas GPx will reduce 
H2O2 to H2O by using an electron from the co-factor glutathione. Monomeric 
glutathione (GSH) is a tripeptide (γ-glutamyl-cysteinyl-glycine) that after its 
oxidation by GPx to glutathione disulfide (GSSG) will have to be recycled by 
glutathione reductase. Glutathione reductase uses NADPH as reducing 
equivalent to reduce GSSG to GSH (Figure 8) (Dringen et al 2005). A large 
body of literature underscores the contribution of these enzymatic anti-
oxidant components to the neuronal resilience against oxidative stress in vitro 
and in vivo (Aoyama et al 2006, Buckman et al 1993, Esposito et al 2000, 
Gonzalez-Zulueta et al 1998, Hoehn et al 2003, Jain et al 1991, Junjing et al 
2010, Kim et al 2002). 
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Figure 8: Pathways of ROS scavenging 
Electrons that prematurely escape from the electron transport chain react with 
oxygen molecules resulting in the generation of superoxide radicals (O2
.-). 
Superoxide dismutase (SOD) will rapidly convert this superoxide to hydrogen 
peroxide (H2O2). Two main enzymatic H2O2-detoxification systems are present 
in neurons: catalase transforms H2O2 to H2O and O2. Glutathione peroxidase 
(GPx) uses glutathione (GSH) as cofactor to reduce H2O2 to H2O. This will 
result in the oxidation of GSH to glutathione sulfide (GSSG). To regenerate 
GSH, glutathione reductase (GR) will use NADPH (generated in the pentose 
phosphate pathway (PPP)) as reducing equivalent. Excessive amounts of H2O2 
can exceed the scavenging capacity of these enzymes, giving rise to hydroxyl 
radicals (OH.) and peroxynitrite (ONOO-) that will damage various cellular 
components due to their highly reactive nature. 
 
The glutathione redox cycling implies that NADPH has to be 
regenerated. The pentose-phosphate pathway (PPP) is believed to be the 
main source of NADPH in neurons (Bolanos and Almeida 2010). This 
metabolic pathway is an alternative route for glucose-6-phosphate besides 
glycolysis and can be divided into two branches (Figure 9). In the oxidative 
branch, the oxidation of glucose will lead to the generation of NADPH and of 
ribose-5-phosphate. The latter can be used for nucleotide synthesis or can be 
recycled into glycolytic intermediates via the non-oxidative branch of the PPP. 
Notably, this non-oxidative branch of the PPP is bidirectional and cells that 
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have high demands for nucleotide precursors will upregulate this branch in 
the opposite direction to increase the production of ribose sugars (Wamelink 
et al 2008). A previous report however suggested that the flux through the 
non-oxidative branch of the PPP is low in neurons (Herrero-Mendez et al 
2009). The NADPH generated in the oxPPP can serve different purposes: for 
antioxidant defense, for lipid synthesis and as a substrate for NADPH oxidase 
(Stanton 2012, Wamelink et al 2008). In neurons, NADPH is believed to mainly 
participate in the recycling of glutathione since lipid synthesis drops after the 
developmental stage of the brain and the expression of NADPH oxidase in 
neurons is low. Several reports have identified NADPH oxidase as an 
important source of superoxides in different pathological conditions (Abramov 
et al 2007, Brennan et al 2009, Cooney et al 2013, Kahles and Brandes 2013), 
even though it is not understood how the fate of NADPH (glutathione 
regeneration versus NADPH oxidase substrate) is regulated in these 
circumstances.  
The PPP turned out to be of vital importance for neuronal anti-oxidant 
defense as inhibition of the PPP flux resulted in neuronal apoptosis due to 
depleted pools of reduced glutathione (Herrero-Mendez et al 2009). This 
study additionally identified a mechanism via which neurons can ensure an 
adequate flux through the PPP. Phosphofructokinase-2,6-
fructosebiphosphatase (PFKFB3)  generates fructose-2,6-biphosphate, which 
acts as an allosteric activator of phosphofructokinase 1 (PFK-1), a rate-
limiting enzyme of glycolysis (Figure 9). Thus, PFKFB3 stimulates PFK-1 
activity and hence, directs glucose-6-phosphate into the glycolysis at the 
expense of the PPP (Eelen et al 2013). In neurons, PFKFB3 protein is nearly 
undetectable because of its continuous posttranslational degradation due to 
ubiquitination by the E3 ubiquitine ligase anaphase-promoting 
complex/cyclosome (APC/C-Cdh1) complex (Herrero-Mendez et al 2009). So, 
by keeping PFKFB3 low, neurons can ensure adequate NADPH regeneration 
through the oxPPP. Even though in baseline conditions, the contribution of 
the oxPPP flux to total glucose oxidation is believed to be rather small, the 
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oxPPP flux can be upregulated in response to oxidative stress (Ben-Yoseph 
et al 1996).  
 
Figure 9: Pentose-phosphate pathway 
Overview of glucose metabolism where glucose-6-phosphate (Glc-6-P) can 
follow two directions: either it undergoes oxidation in the oxidative branch of 
the PPP. This will lead to the production of nucleotide precursor ribose-5-
phosphate (ribose-5-P) and to NADPH, serving as reducing equivalents in 
NADPH consuming processes such as glutathione reduction by glutathione 
reductase. In the non-oxidative branch, ribose-5-phopshate can be 
reconverted to glycolytic intermediates. The activity of phosphofructokinase 1 
(PFK1), catalyzing the conversion of fructose-6-phosphate (fructose-6-P) to 
fructose-1,6-bisphosphate (fructose-1,6-P) will determine the fate of glucose-
6-phosphate. Reduced PFK-1 activity will result in glucose-6-phosphate 
accumulation, facilitating its usage by the PPP. In neurons, low levels of 
PFKFB3 will lead to low levels of fructose-2,6-bisphosphate and thus low 
PFK1-activity, resulting in glucose-6-phosphate shifting towards the oxPPP. 
For reasons of simplicity and clarity, the stoichiometry of the reactions has 
been omitted. 
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Other NADPH regenerating enzymes have been described, but have 
been hardly studied in neurons. Mitochondrial enzymes known for their 
NADPH regenerating capacity are malic enzyme (ME), isocitrate 
dehydrogenase 2 (IDH2) and nicotamide nucleotide transhydrogenase (NNT) 
(Rydstrom 2006). Recently, methylenetetrahydrofolate dehydrogenase, an 
enzyme involved in folate metabolism was identified as a novel NADPH 
producer (Fan et al 2014). Since isolated neuronal mitochondria were shown 
to scavenge H2O2 (Zoccarato et al 2004), these enzymes are potential 
candidates to play a role in mitochondrial NADPH regeneration and 
mitochondrial redox homeostasis (Arkblad et al 2002, Minich et al 2003, Vogel 
et al 1998).  
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5 STROKE & NEURODEGENERATION: TWO BRAIN DISEASES 
EXEMPLIFYING DEREGULATED OXYGEN HOMEOSTASIS 
Acute ischemic stroke and neurodegenerative diseases are common 
neurological conditions. They are both responsible for a huge burden to our 
society. Ischemic stroke is the most obvious example of immediate 
deregulation of oxygen homeostasis. It has however become clear over the 
last decade that also neurodegenerative disorders are associated with oxygen 
stress (Quaegebeur and Carmeliet 2010). 
 
5.1  Ischemic stroke 
5.1.1 INTRODUCTION 
It is nearly impossible to underestimate the medical, social and economical 
impact of ischemic stroke. The World Health Organization reports 15 million 
stroke cases per year worldwide, of which 5 million will result in death and 
another 5 million in severe disability (Broussalis et al 2012). It is currently the 
second leading cause of death worldwide and the leading cause of disability. 
Given the aging population, the disease burden is likely only to increase.  
Acute ischemic stroke is caused by the occlusion of an artery resulting 
in oxygen and nutrient deprivation in a certain brain region. This can have 
devastating consequences: depending on the affected area, a patient can 
experience acute hemiparesis, severe speech disturbances, loss of vision etc. 
The only FDA-approved treatment for ischemic stroke, tissue plasminogen 
activator (t-PA) aims at recanalization of the occluded vessel, but due to a 
narrow therapeutic time window this therapy reaches less than 10% of the 
stroke patients. Therefore, this devastating disease asks for further research 
into novel therapeutic avenues.  
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5.1.2 PATHOPHYSIOLOGY 
a. Arterial occlusion 
A stroke arises when an artery is acutely occluded either by in situ thrombus 
formation or by an embolus originating from the heart, aortic arch or carotid 
artery. Established treatable risk factors for ischemic stroke are diabetes 
mellitus, hypercholesterolemia, arterial hypertension, tobacco usage, cardiac 
disease (atrial fibrillation, ischemic cardiomyopathy, valvular disease) and 
carotid stenosis (Moskowitz et al 2010). Cardiac disease and carotid stenosis 
will increase the risk of emboli formation and can be associated with chronic 
cerebral hypoperfusion, while the other risk factors will compromise cerebral 
blood flow by inducing both structural and functional vessel wall abnormalities 
(Moskowitz et al 2010). Atherosclerosis can be found in the wall of larger 
arteries, whereas smaller intracerebral arterioles can be affected by 
lipohyalinosis. Risk factors such as diabetes and hypertension will also 
interfere with the functional regulation of cerebral blood flow at different 
levels: cerebrovascular autoregulation at the level of large arteries, 
neurovascular coupling at the level of arterioles and microvascular flow 
regulation at the level of the blood-brain barrier might become impaired, 
preventing the brain’s ability to respond to changes in blood pressure and 
neural activity (Iadecola and Davisson 2008). 
 
b. The ischemic cascade in the penumbra 
Following the acute arterial occlusion, the processes that lead up to ischemic 
damage will evolve in a progressive fashion (from minutes to even days). A 
brain region having its blood supply blocked will not undergo the same blood 
flow deficit homogeneously. Due to a certain extent of collateral flow, the 
residual blood flow in the periphery of the ischemic area will be higher than in 
the core. In the core region of the stroke, residual blood flow will be so low that 
neurons undergo immediate necrotic death within minutes. When blood flow 
drops to less than 20% of its normal level, acute ATP depletion will prevent 
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neurons from maintaining their ion homeostasis and energy balance (Astrup et 
al 1981, Lo 2008). Anoxic depolarization following ion pump failure will result in 
cytotoxic edema and rupture of the cell membrane.  
Surrounding this core of irreversibly lost tissue, there is an area that 
only suffers moderate blood flow reduction (20-40% of normal blood flow). 
Here, neurons become dysfunctional, but remain viable for a certain period of 
time. The moderate ischemia will preclude neurons from firing action potentials 
(with electrical silence as a consequence), but will still allow ion pump function 
to a certain extent. This region was named the penumbra, referring to the 
astronomical term indicating the area between complete illumination and 
complete shadow (Astrup et al 1981). This area is of therapeutic interest 
because it is salvageable: within a certain time window it can be saved by 
either reperfusion and/or neuroprotective strategies (Moskowitz et al 2010).  
However, when the blood flow deficit persists, penumbral cells will 
succumb to a complex interplay of deleterious processes. As a consequence, 
the penumbra will shrink in size over time, adding to the necrotic core of 
stroke. Extensive research from the last three decades has identified the 
molecular nature of different events that occur in this so-called “ischemic 
cascade”. Pivotal effectors of neuronal death are glutamate excitotoxicity, peri-
infarct depolarization, calcium overload, mitochondrial dysfunction, oxidative 
stress and programmed cell death (Dirnagl et al 1999, Lo et al 2003, 
Tymianski 2011). Simplified, due to the lack of oxygen, mitochondrial ATP 
production drops. This will increase the formation of oxygen radicals in the 
mitochondria, which will attack the surrounding proteins, lipids and nucleic 
acids. Due to ROS-inactivation of mitochondrial enzymes, mitochondrial 
function is further compromised, creating a vicious cycle between ROS 
generation and mitochondrial bioenergetics (Hertz 2008).  
The disturbed energetic balance will also cause a surge in extracellular 
glutamate levels, since impaired ion pump function will reverse the glutamate 
transporters (Rossi et al 2000) and will depolarize the membrane resulting in 
glutamate release. The rising extracellular concentration of glutamate and the 
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resulting chronic stimulation of the N-methyl-D-aspartate (NMDA) receptor 
(acting as a cation channel) will cause additional membrane depolarization and 
overload neurons with calcium. Toxic intracellular calcium concentrations will 
further aggravate mitochondrial dysfunction and will activate additional sources 
of ROS and reactive nitrogen species generation such as NADPH oxidase and 
neuronal NO synthase. All these processes will in an interactive fashion 
activate effectors of programmed cell death (Dirnagl et al 1999, Lo et al 2003, 
Moskowitz et al 2010).  
 
5.1.3 THERAPEUTIC OPTIONS  
Theoretically, three different approaches exist to treat acute ischemic stroke: 
restoring the blood flow to the ischemic tissue (reperfusion), increasing the 
resilience of the surviving penumbral neurons against further ischemic 
damage (neuroprotection) and facilitating recovery by enhancing repair 
mechanisms (repair). Given the scope of this literature study, the latter will not 
be further discussed. 
 
a. Reperfusion 
Recanalization is currently the only clinically implemented therapy (Jauch et al 
2013). Either by lysing the clot with t-PA (Wardlaw et al 2012), or by 
mechanically retrieving the thrombus with more experimental endovascular 
techniques (Ciccone et al 2013, Lansberg et al 2012), this approach aims at 
removing the thrombus. This will restore the blood flow to the ischemic 
penumbra, halting further ischemic death. Given the ongoing ischemic 
cascade in the penumbral tissue, thrombolysis is only beneficial in a narrow 
therapeutic time window after stroke onset (4.5 hours) and the outcome 
inversely correlates with the interval between onset and thrombolytic therapy 
(Khatri et al 2009, Lees et al 2010). Major efforts are being done to identify this 
penumbra area in stroke patients, as this would select patients that have most 
chance of benefitting from thrombolytic therapies (Albers et al 2006). Current 
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clinical neuroimaging tools allow to detect the discrepancy between the area of 
perfusion deficit and the area of cytotoxic edema, which reflects the ischemic 
penumbra (Straka et al 2010). 
 
b. Neuroprotection 
Neuroprotective therapies refer to any intervention that improves the brain’s 
intrinsic resilience against ischemia (Ginsberg 2008). Similar to the reperfusion 
strategy, this approach aims at rescuing the penumbral area and therefore, a 
certain therapeutic time window needs to be considered as well. Extensive 
research over the past three decades has identified the molecular 
underpinnings of the ischemic cascade, bringing forward viable targets for 
neuroprotection in stroke treatment. The central role for ROS, calcium 
overload, and glutamate excitotoxicity has rationalized preclinical studies with 
ROS scavengers, calcium channel blockers and glutamate antagonists. All of 
these drugs showed a beneficial effect on stroke size in rodent models in 
various studies, further substantiating the contribution of these processes to 
ischemic damage (Ginsberg 2008, Ginsberg 2009).  
In the clinical context, the combination of a neuroprotective drug and 
thrombolysis might synergistically improve stroke outcome: a neuroprotective 
drug may prolong the therapeutic window for thrombolytic drugs (by 
stabilizing the penumbra until reperfusion occurs) and might attenuate the 
reperfusion injury and antagonize some of the detrimental side effects of tPA 
(e.g. stimulation of NMDA-receptor signaling and increased blood-brain-
barrier permeability) (Ginsberg 2008).  
Despite encouraging data from experimental animal models, however, 
decades of research into neuroprotective strategies have faced serious issues 
of translational failure (see also chapter V). This illustrates the compelling need 
for a more integrated and profound understanding of the ischemic cascade 
and possible strategies to interrogate the stroke process.  
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5.1.4 STROKE RESEARCH IN ANIMAL MODELS 
During the last four decades, rodents have been extensively used to model 
focal brain ischemia. Each of the different models has its own advantages and 
limitations. Most often, the middle cerebral artery is occluded via either an 
intraluminal approach or via external suturing. The latter requires a craniotomy 
to visualize the tree of the middle cerebral artery, which is then permanently 
ligated (Robinson et al 1975). Depending on the location of suturing (proximal 
or distal to the origin of the perforating arteries supplying the striatum), the 
striatum is also involved in the ischemic injury (Kuraoka et al 2009). While 
rather invasive given the need for craniotomy, this model allows to generate 
highly reproducible stroke sizes, which are not influenced by anatomic 
differences in the circle of Willis (Kanemitsu et al 2002, Majid et al 2000, 
Schmid-Elsaesser et al 1998).  
The intraluminal filament model provides a less invasive way of 
occluding the middle cerebral artery. A filament is introduced via the internal 
carotid artery until it reaches and occludes the proximal middle cerebral artery 
(Longa et al 1989). This model allows the induction of transient cerebral 
ischemia when retracting the filament. As a drawback, this reperfusion model 
often results in highly variable stroke sizes, where residual blood flow is likely 
to be a crucial determinant (Kanemitsu et al 2002, Majid et al 2000, Schmid-
Elsaesser et al 1998).  
Whereas a neurological examination in rats allows a more detailed 
testing than in mice, stroke studies in mice facilitated the exploration of the 
function of various genes in the pathophysiology of ischemic injury by using 
genetically engineered mice (Canazza et al 2014). In most studies only male 
animals are used to exclude the estrogen-mediated protective effect as an 
additional cause of variability (Hurn and Macrae 2000). Also a pure 
background strain is crucial, as many studies have pointed to a strain-
dependent vulnerability to brain ischemia (Barone et al 1993, Connolly et al 
1996, Fujii et al 1997, Majid et al 2000).  
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The many translational failures in the clinical setting have raised 
skepticism about the relevance of these rodent models for the treatment of 
acute ischemic stroke. Indeed, acute ischemic stroke in humans is a 
multifactorial heterogeneous disease occurring in a mostly aged population 
with different comorbidities such as hypertension and diabetes, each of them 
also affecting the cerebral vasculature. Mice exposed to middle cerebral 
artery ligation are on the contrary gender- and strain-matched, young-adult 
mice, representing a homogeneous population - very much unlike the human 
population suffering from stroke. Therefore, additional studies in aged mice 
with diabetes or hypertension will be crucial to extend the relevance of our 
existing stroke models (Liu and McCullough 2011).  
Nevertheless, a body of literature has also indicated that models of 
brain ischemia in rodents have yielded crucial information for our 
understanding of the cellular and molecular events of the ischemic cascade 
as well as for identifying potential therapeutic targets (Ginsberg 2008). One 
example of an important parallel between the two species is the existence of 
a penumbra. The hemodynamic definition of the penumbra, where residual 
blood flow is between 20-40% of the contralateral hemisphere, is similar 
between rodents and humans (Belayev et al 1997, Heiss et al 1999).  
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5.2 Neurodegeneration 
Next to brain ischemia, where a deregulated oxygen homeostasis is a clear 
characteristic, also neurodegenerative diseases are associated with an 
oxygen imbalance, exemplified by the vascular and metabolic alterations 
observed both in patients as well as in animal models. Evidence for oxidative 
stress and energy insufficiency is abundant in most neurodegenerative 
diseases (Quaegebeur and Carmeliet 2010). Vascular abnormalities such as 
an impaired angiogenic response, neurovascular uncoupling and BBB 
dysfunction (all likely associated with chronic hypoxia) have extensively been 
described, especially in Alzheimer’s disease and amyotrophic lateral sclerosis 
(Quaegebeur et al 2011). Whether or not these changes are the cause or the 
consequence of the disease course, it should be clear that also 
neurodegenerative diseases involve processes that may be affected by PHD 
inhibition, pinpointing PHDs also here as interesting therapeutic targets 
(Quaegebeur and Carmeliet 2010). 
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6 PHD INHIBITION AS A POTENTIAL NEUROPROTECTIVE TARGET? 
 
6.1 Expression of PHDs in the central nervous system 
Prior to any discussion on PHD inhibition as a potential therapeutic target in 
brain diseases, it is important to pursue the expression pattern of PHDs, as 
the different isoforms are known to have a tissue-specific distribution. All 
three PHD isoforms are expressed in the mammalian brain (Lieb et al 2002), 
but show a rather heterogeneous distribution pattern. PHD1 is, at least at 
mRNA level, the most abundant isoform with high levels in the hippocampus, 
cortex and olfactory bulb. PHD2 is also expressed throughout the brain, 
especially in the cortex and hippocampus. PHD3 expression is remarkably 
low in the adult brain (Lein et al 2007).  
 
6.2  Lessons from hypoxic preconditioning and ischemic 
tolerance in the brain 
Hypoxia and oxidative stress can, when prolonged and severe, result in 
neuronal death. However, it has been known for some time that exposing the 
brain to a controlled stressful stimulus, such as oxygen deprivation, to an 
extent that neuronal function is slightly impaired, yet not irreversibly damaged, 
elicits a protective response. In this way, the brain acquires a state of 
ischemic or hypoxia tolerance and will be protected against a subsequent 
lethal stimulus (Gidday 2006). This phenomenon is known as ischemic brain 
preconditioning and has been documented in other organs as well. This 
concept is of great medical interest as it might prove to be a preventive 
strategy in high-risk conditions for cerebrovascular events such as a transient 
ischemic attack or subarachnoid hemorrhage (Dirnagl et al 2009). At first 
glance, hypoxic preconditioning is not implicated in the field of 
neurodegenerative disorders given their chronic nature. Nevertheless, an in-
depth molecular understanding of preconditioning may allow the identification 
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of novel neuroprotective players, which could represent attractive disease 
candidates in both stroke and neurodegeneration (Quaegebeur and Carmeliet 
2010). 
A preconditioning, non-lethal, stimulus is known to profoundly alter 
transcriptional output in the brain (Bernaudin et al 2002, Stenzel-Poore et al 
2003). The HIF family represents one of the most studied hypoxia-sensitive 
transcription factors involved in this genetic reprogramming (Correia and 
Moreira 2009, Harten et al 2009). Both in vitro and in vivo studies show 
increased levels of HIF-1α and its downstream targets VEGF, erythropoietin 
and glycolytic enzymes upon exposure to cellular stress (Baranova et al 2007, 
Sharp and Bernaudin 2004). Given the well-documented neurotrophic effects 
of the effector molecules VEGF (Quaegebeur et al 2011) and erythropoietin 
(Brines and Cerami 2005), HIF-1α is arguably pinpointed as moderator of 
neuroprotection. Further in vivo characterization of the role of HIF-1α in acute 
cerebral ischemia yields, however, conflicting data (Baranova et al 2007, Chen 
et al 2009, Helton et al 2005). Pharmacological manipulation of HIF-1α also 
demonstrates diverging effects on stroke outcome (Baranova et al 2007, Chen 
et al 2009, Chen et al 2008a, Helton et al 2005, Ratan et al 2008, Siddiq et al 
2005, Zhou et al 2008). This may be related to the dual activity of HIF-1α, 
which not only activates survival-promoting pathways, but also triggers pro-
apoptotic proteins such as Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 
(BNIP3) and p53-upregulated mediator of apoptosis (PUMA) (Chen et al 
2008b). Taken together, the overall effect of HIF-1α on neuronal cell fate 
appears to be context specific and requires further study. 
 
6.3 PHD inhibition: the past, the present and the future  
As HIF-1α levels are mainly regulated by the activity of the PHDs, inhibition of 
PHDs has become an attractive strategy in preconditioning therapy. Current 
available PHD inhibitors act as iron chelators or 2-oxoglutarate analogs, 
depleting the enzyme cofactor iron or competing with its cosubstrate 2-
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oxoglutarate, respectively (Fraisl et al. 2009). The neuroprotective effects of 
these agents have been validated in preclinical stroke models (Baranova et al 
2007, Freret et al 2006, Hamrick et al 2005, Li et al 2008, Nagel et al 2011, 
Ogle et al 2012, Reischl et al 2014, Siddiq et al 2005), with in some reports 
evidence for a, at least partially, HIF-1α-mediated effect (Baranova et al 2007, 
Hamrick et al 2005, Ogle et al 2012). However, as all these studies have been 
rather descriptive, the precise mechanism of protection remains obscure. 
Interestingly, a beneficial effect of post-stroke administration was reported as 
well (Nagel et al 2011, Ogle et al 2012, Reischl et al 2014).  
Inspired by the neuroprotective role of the PHD/HIF pathway in brain 
ischemia, PHD inhibitors are assessed as treatment design for 
neurodegenerative disorders as well. Already in 1991, clinical efficacy of iron 
chelators was tested in Alzheimer’s disease patients (Crapper McLachlan et al 
1991). Desferrioxamine, another iron chelator, was reported to slow down 
neurodegeneration in rodent models of Parkinson’s disease (Ben-Shachar et 
al 1991, Lan and Jiang 1997). More recently, novel iron chelating drugs 
resulted in a survival advantage in an amyotrophic lateral sclerosis (ALS) 
mouse model (Kupershmidt et al 2009).  
Overall, the fact that the PHD-HIF pathway is a putative player in 
cerebral ischemic preconditioning together with the numerous observations of 
neuroprotective properties of various aspecific PHD inhibitors, render PHD 
inhibition an attractive approach in the treatment of diverse neurological 
conditions. However, an important setback of these drugs is that they lack 
specificity. Indeed, iron chelating drugs will not only inhibit PHDs, but all other 
iron-dependent enzymes as well. The resulting iron depletion will also lead to 
anemia. The inhibition by 2-oxoglutarate analogues is not specific for PHDs 
either as more than 50 2-oxoglutarate dioxygenases have been described, 
which will also be inhibited by these drugs (Fraisl et al 2009, Loenarz and 
Schofield 2008).  
Why would this lack of specificity be a concern for therapeutic utility in 
a clinical setting? Their off-target effects might bring about an unfavorable 
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safety profile and complicate their clinical use. Ideally, inhibitors of specific 
PHD iso-enzymes would allow us to refine the concept of PHD inhibition by 
specifically targeting a disease state without causing unwanted effects. 
Especially PHD1- and PHD3-specific inhibitors might be well tolerated given 
the absence of major physiological deficits in PHD1-/- and PHD3-/- mice 
(Aragones et al 2008, Taniguchi et al 2013). Furthermore, the lack of 
specificity confounds the role and downstream effects of specific PHD 
isoforms in neuronal injury. Therefore, in vivo analyses of the disease- and 
cell-specific role of PHD are essential in pursuing the clinical validation of 
PHD inhibitors. So far, a single in vitro study implicated PHD1 in the 
neuroprotective response to oxidative stress (Siddiq et al 2009), two studies 
pinpointed PHD2 inhibition as a potential target in transient brain ischemia 
(Chen et al 2012, Kunze et al 2012) and PHD3 was linked to neuronal 
apoptosis during development (Bishop et al 2008, Lee et al 2005).  
In conclusion, an important role for PHDs in the brain can be assumed, 
and a growing body of evidence points to the neuroprotective potential of 
PHD inhibition. However, important gaps in our understanding have to be 
resolved before this promising preclinical therapeutic target will reach human 
bedside. 
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Chapter II  
 
AIMS 
 
 
Organisms have developed a variety of mechanisms to sense, transduce and 
regulate adaptive responses to a shortage in oxygen. At the cellular level, the 
prolyl hydroxylase domain proteins (PHDs) take on a leading role in 
maintaining this oxygen homeostasis.  
Previous work of the host laboratory showed that PHD1 deficient muscle is 
resistant towards limb ischemia. Interestingly, this ischemia tolerance was 
attributed to a shift from aerobic metabolism to anaerobic glycolysis. The 
brain, as the largest consumer of oxygen and nutrients, is a very expensive 
organ with a delicate metabolic balance. Disturbances in this homeostasis 
can result in devastating brain diseases such as ischemic stroke and might 
contribute to neurodegenerative disorders. Yet, surprisingly little is known 
about the functions of the different PHD isoforms in the brain and even less 
about whether and how modulation of metabolic pathways could affect 
neuronal injury.  
This prompted a number of outstanding questions on the function of PHDs in 
brain ischemia: would PHD1 deletion also confer ischemia tolerance in the 
brain? What would this implicate for diseases such as stroke and 
neurodegeneration? And even more tantalizing, would a similar metabolic shift 
as seen in PHD1 deficient muscle also protect against neuronal injury? 
We formulated the specific aims for this doctoral work as follows: 
• What is the effect of PHD1 deficiency on infarct size in a model of stroke in 
rodents? Are the potential effects PHD1-specific, or do PHD2 and PHD3 
deficiency affect stroke size as well? 
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• Via which mechanisms and cellular mediators does loss of PHD1 impact 
on brain ischemia? More specifically, given the metabolic phenotype in the 
PHD1 deficient muscle, what is the effect of PHD1 deletion on neuronal 
metabolism? How does this relate to the known effects of PHD1 deficiency 
on metabolism and does this provide us with additional insights into 
neuronal metabolism? 
• Does the effect of PHD1 deficiency in ischemic stroke have translational 
potential towards new therapeutic strategies? 
• Do the findings have implications for neurodegenerative diseases as well? 
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Chapter III  
 
MATERIALS & METHODS 
 
 
1. MOUSE STRAINS USED IN THIS STUDY 
PHD1-/- (Aragones et al 2008), PHD2lox/lox (Mazzone et al 2009) and PHD3-/- 
mice (Bishop et al 2008) were previously generated in the lab. The Nestin-Cre 
mice were on a C57/Bl6 background and were a kind gift from Dr. R. Klein 
(MPI, Germany). Nestin-Cre mice were intercrossed with PHD2lox/lox mice. 
Nestin Cre+ PHD2lox/lox mice were compared with Nestin Cre- PHD2lox/lox mice. 
Mice overexpressing human mutant SOD1G93A were provided by Dr. C. Kunst. 
They were backcrossed for more than ten generations into a FVB 
background. The genetic background of the PHD1-/- SOD1G93A mice was 
FVB(50%)/129S6(25%)/swiss(25%). The genotype of these transgenic animal 
models was determined by PCR. Wild type C57/Bl6 mice were obtained from 
the KU Leuven animal facility. For each transgenic mouse line, littermates or 
age-matched wild type control mice were used. Housing and experimental 
animal procedures were approved by the Institutional Animal Care and 
Research Advisory Committee of the University of Leuven, Belgium. 
 
2. INDUCTION OF ISCHEMIC STROKE VIA PERMANENT MIDDLE CEREBRAL ARTERY 
OCCLUSION 
Brain ischemia was induced in 8-11 weeks old male wild type and PHD1-/- 
mice using the permanent middle cerebral artery occlusion (pMCAO) model 
as previously described (Kuraoka et al 2009). Both C57Bl/6 and 129S6 
backgrounds were used, as indicated. Under the surgical microscope, a skin 
incision was made between the left orbit and tragus. The zygomatic arch was 
removed and temporal muscle retracted laterally. A 2-mm burr hole was made 
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with a microdrill through the outer surface of the semitranslucent skull over 
the visually identified middle cerebral artery. The dura was carefully opened 
and the M1 branch of the MCA exposed and ligated producing a permanent 
ligation of the distal middle cerebral artery.	   The wound was sutured and 
temperature was controlled by keeping the mice on a heating plate at 37 °C 
until they regained full consciousness. 
 
3. HISTOLOGICAL ANALYSIS OF INFARCT SIZE 
At 24 hours after ischemia, brains were removed, sliced coronally at 1 mm 
intervals and stained by immersion in vital dye (2%) 2,3,5-triphenyltetrazolium 
hydrochloride (TTC) for 30 minutes. TTC will be reduced by active 
mitochondrial dehydrogenases, indicative of viable tissue, resulting in the 
formation of a deep-red product (formazan) (Bederson et al 1986). For each 
coronal slice the unstained portion was delineated, and infarction area was 
calculated as the ratio of the unstained area (white) over the total 
bihemispheric area with Image J.  
 
4. ADHESIVE TAPE REMOVAL TEST 
The performance in the adhesive removal test was used as a functional 
parameter to monitor the functional impact of the stroke as previously 
described (Bouet et al 2009). Mice were trained during 7 days prior to the 
stroke to avoid any training effect. A 3mm x 4mm piece of tape was attached 
to both forepaws. Time to sensation and to removal was recorded for both 
paws. Three separate measurements were done at day 1, 4, 8 and 11 post-
stroke.  	  
5. MORPHOLOGICAL AND HISTOLOGICAL ANALYSIS OF BRAIN VASCULATURE  
To compare large arteries and arterioles in wild type and PHD1-/- mice, mice 
were perfused transcardially with saline followed by 4% PFA. Brains were 
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dissected and post-fixed in 4% PFA overnight at 4°C, cryoprotected in 
sucrose 20% and embedded in optimal cutting temperature (OCT) embedding 
medium. Serial coronal cryosections of 10µm thickness were incubated 
overnight with the primary antibody anti-αSMA-Cy3 (C6198, Sigma, 1/500). 
Slices were mounted with Prolong Gold + DAPI (Dako). 
To assess vessel perfusion, wild type and PHD1-/- mice were injected 
via the tail vein with fluorescein isothiocyanate (FITC)- conjugated dextran 
(molecular weight 2x106 Da, Sigma) shortly before transcardial perfusion, and 
were thereafter processed for cryosectioning.  
The visualization of the pial collateral circulation in wild type and PHD1-
/- mice was done via vascular corrosion casting as previously described  
(Krucker et al 2006, Zhang et al 2010). The thoracic aorta was cannulated 
retrogradely and 1 ml of freshly prepared polyurethane resin (PU4ii, VasQtec) 
was infused into the cerebral vasculature. The PU4ii mixture was freshly 
prepared by adding 0.8 g of hardener (VasQtec) to PU4ii diluted in 
dimethylethylketone, immediately before the injection. Following resin 
injection, mice were perfused with 4% PFA. After 5 days at room temperature 
to ensure polymerisation of the resin, brains were dissected and were 
repeatedly rinsed in 30% KOH  
Images of the corrosion casting were captured by Zeiss LSM 780 
confocal microscope (Carl Zeiss). The number of collaterals was counted 
manually per hemisphere. Collaterals were defined as vessels connecting the 
tree of the anterior cerebral artery with the tree of the middle cerebral artery, 
or connecting one arteriole from the middle cerebral artery with an arteriole 
from the same vascular tree.  
 
6. ISOLATION AND CULTURE OF MURINE CORTICAL NEURONS 
Cultures of cortical neurons were prepared as previously described. Briefly, 
neuron cultures from WT and PHD1-/- mice were prepared from the cortices of 
embryonic day 14.5-15.5 mice as described previously (Thathiah et al 2009) 
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and maintained in serum-free NeuroBasal containing 25mM glucose 
(Invitrogen), supplemented with 0.5mM glutamine and B27 supplement 
(Invitrogen, 1/50). After 3 days in culture, 8µM cytosine arabinoside (Sigma) 
was added to prevent non-neuronal proliferation. These cultures contained 
>98% MAP2+ neurons after 7 days in culture, as confirmed by 
immunostaining. 	  
7. LENTIVIRAL TRANSDUCTIONS 
Lentiviral shRNA vectors against glucose-6-phosphate dehydrogenase 
(G6PD), PHD2, PHD3, HIF-1α and HIF-2α, were ordered from the TRC 1.5 
lentivirus-based shRNA library (Sigma) consisting of almost 200,000 pre-
cloned shRNA vectors targeting more than 22,000 human and 20,000 mouse 
genes. The shRNA ID nummers were TRCN0000041443 and 
TRCN0000041447 for G6PD, TRCN0000232222 for HIF-1α, 
TRCN0000082306 for HIF-2α, TRCN0000009740 for PHD2, 
TRCN0000009753 for PHD3. A similar nonsense scrambled shRNA sequence 
was used as a negative control for all these experiments. Production of 
lentiviruses by transfection into 293T cells was as described (Carlotti et al 
2004). After 2 days in culture, the cultured neurons were exposed overnight to 
a multiplicity of infection of 10 after which the medium was refreshed. 
Knockdown efficiency was assessed 4 days after transduction by qPCR. 	  
8. OXYGEN-NUTRIENT DEPRIVATION ASSAY IN VITRO   
After 7 days in culture, neurons were exposed for 2 hours to 0.1% oxygen in 
nutrient-deprived medium (Dulbeco’s Modified Essential Medium (D5030, 
Sigma) lacking glucose, glutamine and pyruvate, supplemented with 7.5 mM 
NaHCO3
- and 5 mM HEPES and adjusted to pH of 7). After this period of 
oxygen-nutrient deprivation, neurons were re-exposed to ambient air and 
regular nutrient-containing culture medium (neurobasal medium 
supplemented with 0.5 mM glutamine and B27 supplement minus anti-
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oxidants, both from Invitrogen). Leaving out anti-oxidants in the medium 
prevented the masking of a neuron-intrinsic improvement of ROS 
detoxification, which is crucial in all neuronal cell death assays relating to 
oxidative stress. Neuronal cell death was quantified 24 hours later by 
measuring LDH release in the culture medium using the Cytotoxicity Detection 
Kit (Roche applied sciences). LDH release after maximal lysis of control wells 
(with Triton-X) was used to calculate the relative cell death.  
 
9. METABOLIC FLUX ASSAYS 
Metabolic fluxes were measured using radioactive labeled tracer glucose, 
glutamine and lactate (all tracers were from American Radiolabeled 
Chemicals). All fluxes were corrected for the specific activity. 
Glycolysis was measured as 3H2O formation using [5-
3H]-D-glucose as 
previously described (De Bock et al 2013). Briefly, at day in vitro (DIV) 7, 
cortical neurons were incubated for 2 hours with medium containing 5 mM 
glucose and labeled 5-3H-glucose (0.5 µCi/mmol). After this incubation period, 
the medium was transferred to glass vials, which were closed with rubber 
stoppers each containing a hanging well with a soaked (200µl Milli-Q water) 
filter paper (1cm x 6cm) to capture the evaporated 3H2O. The vials were 
incubated for 48 hours at 37°C. Afterwards, the filter papers were transferred 
to scintillation vials containing 5ml of scintillation fluid (Lumasafe 3087, Perkin 
Elmer) and counted with the Tri-Carb 2900TR Liquid Scintillation Analyzer 
(Perkin Elmer). A correction factor of 22.6 was used to correct the glycolysis 
flux for the percentage of 3H2O captured by the filtered paper. This correction 
factor has been determined in earlier pilot experiments in the host laboratory.  
Glucose oxidation was assessed as 14CO2 formation using [6-
14C]-D-glucose 
as previously described (De Bock et al 2013). At DIV7, cortical neurons were 
incubated for 2 hours with medium containing labeled [6-14C]-D-glucose (1 
µCi/mmol). Perchloric acid (HClO4) (250µl, 3M) was used to stop cellular 
metabolism and to lyse the cells. The release of intracellular CO2 was 
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captured by Whatman filter papers soaked in hyamine covering the lid over a 
period of 24 hours at room temperature. Next, the filter papers were 
transferred to scintillation vials and counted by the Scintillation Analyzer. 
Oxidative Pentose Phosphate Pathway (oxPPP) was measured as 14CO2 
formation using [6-14C]-D-glucose (14CO2 formation only in the TCA cycle) and 
[1-14C]-D-glucose (14CO2 formation both in the TCA cycle and the oxPPP). 
Cortical neurons were cultured in parallel wells and incubated with medium 
containing [6-14C]-D-glucose (1 µCi/mmol) or medium containing [1-14C]-D-
glucose (1 µCi/mmol). Released 14CO2 was captured in a similar manner as 
described above for glucose oxidation. The [6-14C]-glucose flux was then 
subtracted from the [1-14C]-glucose flux. The relative contribution of the 
oxPPP flux to glucose metabolism was assessed by including glucose uptake 
in the relative flux measurements as described before (Aschroft et al 1972).  
Glutamine oxidation was measured as 14CO2 formation using [U-
14C]-
glutamine. Cortical neurons were incubated with medium containing [U-14C]-
glutamine (as well as glucose). Similar as described above for glucose 
oxidation, cells were lysed with HClO4 and 
14CO2 was captured in hyamine-
soaked filter papers. 
Lactate oxidation was measured in a similar way as 14CO2 formation after 
incubation with glucose-, lactate- and glutamine-containing medium with [U-
14C]-lactate. 
Oxygen consumption rate (OCR) was measured using the extracellular flux 
analyzer XF24 (Seahorse Bioscience Inc.). Cortical neurons were plated and 
grown for 7 days in a Seahorse XF24 tissue culture plate. At DIV7, the oxygen 
consumption rate was measured over a period of 2 minutes. In baseline 
conditions, 5 consecutive measurements of OCR are done. Next, oligomycin, 
a blocker of ATP synthase is injected at 12 µM (concentration in well 1.2 µM). 
The drop in OCR reflects the oxygen consumption serving ATP production. In 
parallel well dinitrophenol (DNP), a mitochondrial uncoupler is injected at 1 
mM (concentration in well 100 µM). This will force neurons to use their 
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maximal mitochondrial capacity in order to preserve the mitochondrial 
membrane potential. The increase in OCR reflects the reserve capacity of 
mitochondria. As a second injection Antimycin A is added at 10 µM 
(concentration in well 1 µM), a complex III inhibitor. This shuts down the 
electron transport chain activity abolishing the mitochondrial oxygen 
consumption. The residual OCR corresponds to the non-mitochondrial 
oxygen consumption. All mitochondrial inhibitors are from Sigma. 	  
10. ASSESSMENT OF REACTIVE OXYGEN SPECIES  
The scavenging capacity of reactive oxygen species (ROS) was measured by 
assessing the detoxification rate of H2O2 after loading the cells with 10 µM 5-
(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate (CM-H2-
DCFDA, Molecular Probes, Invitrogen). CM-H2-DCFDA is metabolized by 
intracellular esterases to a non-fluorescent product, which is oxidized to the 
fluorescent product CM-DCF, by H2O2. The dye was washed away and cells 
were exposed to 100 µM H2O2. Fluorescence was measured over time with a 
fluorescent plate reader.  
 
11. MEASUREMENT OF ENERGY CHARGE 
Energy charge was monitored over 8 hours of oxygen-nutrient deprivation. 
Cells were exposed for 8 hours to 0.1% oxygen in nutrient-deprived medium. 
Cells were harvested after 4, 6 and 8 hours in 100 µl ice cold 0.4 M perchloric 
acid supplemented with 0.5 mM EDTA. pH was adjusted by adding 100 µl of 
2 M K2CO3. 100 µl of the mixture was injected onto an Agilent 1260 HPLC 
equipped with a C18-Symmetry column (150 x 4.6 mm; 5 mm) (Waters), 
thermostated at 22.5 °C. Flow rate was kept constant at 1 ml/min. A linear 
gradient using solvent A (50 mM NaH2PO4, 4 mM tetrabutylammonium, 
adjusted to pH 5.0 using H2SO4) and solvent B (50 mM NaH2PO4, 4 mM 
tetrabutylammonium, 30% CH3CN, adjusted to pH 5.0 using H2SO4) was 
accomplished as follows: 95% A for 2 min, from 2 to 25 min linear increase to 
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100% B, from 25 to 27 min isocratic at 100% B, from 27 to 29 min linear 
gradient to 95% A and finally from 29 to 35 min at 95% A. Detection of ATP, 
ADP and AMP occurred at 259 nm. The energy charge is calculated as ([ATP] 
+ ½ [ADP] / [ATP] + [ADP] + [AMP]) 
 
12. IMMUNOCYTOCHEMISTRY 
Cortical neurons grown on Willco-Dish glass bottom dishes (Ibidi) were after 7 
days in culture fixed with PFA 4% for 10 minutes. After permeabilization for 10 
minutes in 0.25% Triton and blocking 30 minutes with pre-immune serum, 
cells were incubated overnight with the appropriate primary antibodies. 
Following antibodies were used anti-TOMM20 (ab56783, Abcam; 1/200), anti-
MAP2 (M3696, Sigma, 1/500), anti-GFAP (G3893, Sigma, 1/500), anti-NG2 
(AB5320, Chemicon, 1/200), anti-Olig2 (AB9610, Chemicon, 1/20 000). Next 
day, sections were incubated with the appropriate fluorescently conjugated 
secondary antibody (Alexa-568 or Alexa 488, Molecular Probes, Invitrogen).  
For Periodic Acid Schaff  (PAS) staining, cells were exposed for 10 
minutes to periodic acid, after which Shiff reagens (De Tomasi, Prosan NV) 
was added for 5 minutes. 10 µm thick cryofixed sections through embryonic 
brains from wild type and PHD1-/- embryos at E14.5-15.5 were stained with 
Nissl.  
 
13. RNA AND DNA ANALYSIS 
Total RNA was extracted from cultured cortical neurons using the RNeasy 
microkit (Qiagen), and reverse transcribed using the Quantitect Reverse 
Transcription kit (Qiagen) according to the manufacturer’s instructions. Total 
RNA was extracted from dissected brain tissue using the Trizol-chloroform 
extraction. After tissue homogenization with Trizol, chloroform was added to 
separate the aqueous phase. After centrifugation and addition of ethanol, 
samples underwent a RNA clean-up on a RNeasy mini column (Qiagen 74104) 
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with DNAse I treatment (Invitrogen 12185010). Gene expression analysis was 
performed by Taqman quantitative RT-PCR, using premade primer sets 
(Applied Biosystems). Expression levels were quantified relative to the 
expression level of housekeeping genes (β-actin or HPRT).  
For mitochondrial DNA copy measurement, total DNA was extracted 
from cell lysates. The amount of mitochondrial DNA relative to nuclear 
genomic DNA was determined by quantitative PCR using homemade primers 
for cytochrome b (mitochondrial) and RPL13A (nuclear): NC FOR2 
agacctgaagaggcttcgctaa; NC REV2 cagcttgcgggtcaagct; NC probe2 
ccaccgtcccttccagctaccatccta; MIT PROBE aca att agg gtt tac gac ctc gat gtt 
gga t; MIT FOR ttg atc aac gga cca agt tac c; MIT REV cgt tga aca aac gaa 
cca tta ata g.  
 
14. PROTEIN ANALYSIS 
Nuclear protein extraction was done by using the NEPER kit (Pierce, Thermo 
Scientific) according to manufacturer’s instructions, in the presence of 
protease and phosphatase inhibitors (Roche). Lysates were separated by 
SDS-PAGE under reducing conditions, transferred to a nitrocellulose 
membrane (Life Technologies) and analyzed by immunoblotting. Primary 
antibodies used were goat anti-HIF-1α (AF1935, R&D Systems, 1:200), goat 
anti-HIF-2α (AF2997, R&D Systems, 1:200). Equal loading was verified by 
incubation with rabbit anti-βactin (13E5; No. 4970), rabbit anti-βtubulin (No. 
2144), and rabbit anti-lamin A/C (No. 2032) (all from Cell Signaling 
Technology, Bioké). Appropriate secondary antibodies were from Dako 
(Enschede, the Netherlands). Signal was detected using the ECL system 
(Amersham Biosciences, GE Healthcare) according to the manufacturer’s 
instructions. 	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15. INTRACEREBROVENTRICULAR DELIVERY OF ANTISENSE OLIGONUCLEOTIDES 
AGAINST PHD1 IN STROKE 
Oligonucleotides directed against murine PHD1 were synthesized and purified 
by Isis Pharmaceuticals as previously described (Bennett and Swayze 2010). 
These antisense oligonucleotides (ASOs) are directed against the regions 
within the coding region and 5’ and 3’ untranslated region of the PHD1 
mRNA. The principle of knockdown by these ASOs is that after binding to 
complementary target RNA through Watson-Crick base-pairing, the target 
RNA will be degraded by RNaseH-mediated RNA degradation. Additional 
modifications consisting of a O-(2-methoxy)ethyl substitution at the 2’ position 
and phosphorothioate modifications were created to increase the resistance 
of the ASOs against nuclease activity and in this way promote their stability. 
Three top ASOs of 20 nucleotides long were selected for further investigation.  
Knockdown efficiency was tested in cultured cortical neurons. At DIV2, 
cortical neurons were exposed to 0.5 µM and 1 µM of anti-PHD1 ASOs. To 
ensure correct dosing, the absorbance at 260 nm was regularly measured in 
the stock solution. An oligonucleotide that targets murine MALAT-1 (non 
coding RNA in the nucleus) was used as control ASO. According to the 
experience of Isis Pharmaceuticals, this oligonucleotide does not induce a 
phenotype in the central nervous system and is well tolerated in neurons. At 
DIV7, cortical neurons were harvested for RNA extraction and qPCR for 
PHD1, PHD2 and PHD3.  
One out of the three ASOs with the highest efficiency and specificity 
was selected for further in vivo studies. A dose of 75 µg ASO/day was infused 
into the left lateral ventricle of male C57/Bl6 mice (age 7-8 weeks), using 
Alzet® osmotic pumps (model 2004, Cupertino), connected with a catheter to 
a brain infusion cannula as previously described (Storkebaum et al 2005). The 
brain infusion assembly was filled with a solution, containing the ASO diluted 
in artificial CSF (aCSF) or with aCSF alone (saline control). For the in vivo 
studies both saline and a non-RNAas H active ASO to human huntingtin was 
used as control. The composition of the aCSF was 150 mM Na+, 3 mM K+, 1.4 
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mM Ca2+, 0.8 mM Mg2+, 1 mM PO4
3- and 155 mM Cl-. After anesthesia with 
ketamine and xylazine, the osmotic pump was subcutaneously inserted in the 
midscapular area on the back of the mouse. After exposing the skull through 
a midline sagittal incision, a hole was drilled through the skull, and the 
cannula placed using the following stereotactic coordinates: 0 mm posterior 
and 1 mm lateral to bregma, and 2 mm deep from skull surface. After 10 days 
of infusion, brains were harvested from a series of test mice to assess 
knockdown efficiency. Two weeks after the infusion, pMCAO was performed  
 
16. ROTAROD AND SURVIVAL ANALYSIS IN SOD1G93A MICE 
Female PHD1+/+ and PHD1-/- x SOD1G93A littermates were followed up twice a 
week by an investigator who was blinded to the genotype. Motor performance 
was tested by the use of the rotarod (Ugo Basile) twice a week from the age 
of 60 days. Mice were tested for their ability to stay on the rotarod, which has 
a constant rotating speed of 15 rotations per minute, for 3 minutes. Time of 
onset of paralysis was determined as the time when mice fell of the rotarod 
before 1 minute (on average in 5 separate trials). Body weight was also 
followed up twice a week. Time of death was scored as the day when the 
mice had lost 20% of their pre-symptomatic body weight or when they were 
no longer able to right themselves within 30 seconds when placed on their 
back. 
 
17. STATISTICS 
All data are reported as mean ± SEM of the indicated number of experiments 
or mice. For in vitro data the N-values indicate the number of independent 
experiments performed with different cultures of WT and PHD1-/- cortical 
neurons. When inter-experimental variability was too large, representative 
experiments are shown (with technical replicates; as indicated). In the shown 
representative experiment the differences between the conditions reflects the 
average of the pooled experiments. In that case, at least 3 independent 
	   66 
experiments were performed each showing statistical significance (p<0.05) 
using the appropriate statistical test. Student’s t-test was used unless another 
statistical test is mentioned. 
In some PHD1-/- mice no infarct was visible after ligation of the middle 
cerebral artery (indicating complete protection against brain ischemia), 
thereby disturbing normal Gaussian distribution. In these cases, we used non-
parametrical Mann-Whitney-U test to determine statistical differences 
between the two groups. Kaplan-Meier statistics were used for analysis of 
rotarod performance and survival in SOD1G93A mice. We used Prism v5.0 for 
all statistical calculations. P<0.05 was considered statistically significant. 
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Chapter IV  
 
RESULTS 
 
 
PHD1-/- MICE ARE PROTECTED AGAINST ISCHEMIC STROKE AFTER 
PERMANENT MCAO 
Ischemic stroke is the most striking and acute example of a collapsing oxygen 
homeostasis in the brain. We hypothesized that deletion of one of the PHD 
isoforms would increase the brain’s resilience against ischemia. To address 
the role of the different PHD isoforms, we induced acute ischemic stroke in 
different PHD-deficient mice. Through a permanent ligation of the middle 
cerebral artery, distal to the lenticulostriate arteries, acute ischemia in the 
sensorimotor cortex was induced. We chose this distal model of permanent 
middle cerebral artery occlusion (pMCAO) because it is known for its high 
reproducibility and low mortality rates (Kuraoka et al 2009). Since we earlier 
reported that mice lacking PHD1 are protected against limb and liver ischemia 
(Aragones et al 2008, Schneider et al 2009), we initiated our stroke studies in 
homozygous PHD1 deficient (PHD1-/-) mice.  
We performed pMCAO in PHD1-/- mice and wild type males (C57/Bl6 
background), aged 8-11 weeks. To assess the infarction area, we stained 
brain slices with the vital dye TTC (2,3,5-triphenyltetrazolium chloride) at 24 
hours post-pMCAO (when lesion size after pMCAO is maximal (Kuraoka et al 
2009)). This analysis revealed that brain infarction is largely attenuated in 
PHD1-/- mice with a ca. 70% reduction in ischemic lesion size in PHD1-/- mice 
versus control wild type mice (Figure 1A-C).  
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Figure 1: PHD1 deficiency reduces infarct size after pMCAO (C57/Bl6 
strain) 
Representative brain slices after TTC staining, delineating the infarct zone as 
unstained area (white), from wild type (WT) (A) and PHD1-/- mice (B) 24 hours 
after pMCAO. Quantification of the stroke area as percentage of the total 
bihemispheric area is shown in C (N=6, *P<0.05, Mann-Whitney U test). Scale 
bar: 1 mm. 
 
To test whether this smaller infarct size also resulted in improved 
functional outcome, we used the adhesive tape removal test (Bouet et al 
2009). This test was specifically developed as a very sensitive assessment of 
sensory and motor coordination in this distal model of pMCAO, where more 
classic motor tests such as grip strength and rotarod performance are 
unaffected. In wild type mice, as expected, an important delay in the time 
needed to sense the tape on their affected forepaw as well as in the time 
necessary to remove the tape arose after ischemia-induction (Figure 2A,B). In 
contrast, post-stroke functional performance in PHD1-/- mice was hardly 
affected (Figure 2A,B). Of importance, this functional difference between wild 
type and PHD1-/- mice persisted over a longer period of time (Figure 2A,B), 
indicating that the protective effect in the PHD1-/- mice was not a temporary 
effect, only observable at 24 hours after the ligation.  
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Figure 2: PHD1 deficiency improves functional performance in the 
adhesive tape removal test after stroke induction 
(A) Average time needed before the WT (grey) and PHD1-/- (blue) mice sense 
the presence of the tape, assessed 1 day before and at day 1, 4, 8 and 11 
post-stroke (N=7-8, **P<0.01, two-way ANOVA). (B) Average time needed 
before the mice successfully removes the tape, assessed 1 day before and at 
day 1, 4, 8 and 11 post-stroke (N=7-8, **P<0.01, two-way ANOVA).  
 
 
Differences in stroke size depending on the mouse strain used have 
been extensively reported in the literature (Barone et al 1993, Connolly et al 
1996, Fujii et al 1997, Majid et al 2000). Differences in vascular anatomy (e.g. 
completeness of circle of Willis), vascular responses to anesthetics, neuron-
intrinsic resilience and many other factors were described to underlie this 
strain-specific vulnerability (Beckmann 2000, Fujii et al 1997). Therefore, to 
exclude strain-specific protection, we also performed pMCAO also in the 
129S6 strain.  The average stroke size in wild type mice was smaller in the 
129S6 than in the C57/Bl6 strain. Still, PHD1-/- brains were protected against 
ischemic injury to a similar extent as shown by TTC staining (Figure 3A-C). 
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Figure 3: PHD1 deficiency reduces infarct size after pMCAO (129S6 
strain). 
Representative brain slices after TTC staining, delineating the infarct zone as 
unstained area (white), from WT (A) and PHD1-/- mice (B) 24 hours after 
pMCAO. Quantification of the stroke area as percentage of the total 
bihemispheric area is shown in C (N=6-9, **P<0.01, Mann-Whitney U test). 
Scale bar: 1 mm.  
 
To address the specificity of this ischemia tolerance for PHD1, we also 
assessed the effect of PHD2 and PHD3 deficiency on stroke size. As 
homozygous PHD2 deficiency causes embryonic lethality (Takeda et al 2006), 
we induced a neural-specific PHD2 deletion by intercrossing PHD2lox/lox mice 
with Nestin-Cre mice (Tronche et al 1999). Infarct size was not affected in 
Nestin-Cre+ x PHD2lox/lox mice when compared to Nestin-Cre- x PHD2lox/lox mice 
(Figure 4A-C). Also no differences in stroke size could be observed in PHD3-/- 
mice as compared to wild type mice (Figure 4D-F). In addition, PHD1-/- brains 
did not have augmented transcript levels of the other oxygen sensors PHD2 
and PHD3 (relative mRNA levels in PHD1-/- brain compared to WT brain: 106.2 
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± 5.0% for PHD2 and 105.7 ± 2.2% for PHD3; N=4; P=0.34 for PHD2 mRNA 
and P=0.35 for PHD3 mRNA). This suggests that constitutive PHD1 deficiency 
does not elicit compensatory changes in the other oxygen sensors, further 
substantiating a PHD1-specific neuroprotective effect in stroke.  
 
 
Figure 4: Deficiency of PHD2 or PHD3 does not affect infarct size after 
pMCAO. 
Representative images from TTC staining in Nestin-Cre- PHD2lox/lox versus 
Nestin-Cre+ PHD2lox/lox (A,B) and WT versus PHD3-/- mice (D,E). Quantification 
of the stroke area as percentage of the total bihemispheric area is shown in 
(C) for Nestin-Cre- PHD2lox/lox versus Nestin-Cre+ PHD2lox/lox (N=3; P=0.86) and 
in (F) for WT versus PHD3 -/- mice (N=7-8; P=0.14).  
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PHD1-/- BRAIN VASCULATURE DOES NOT SHOW MAJOR MORPHOLOGICAL OR 
FUNCTIONAL ALTERATIONS  
Angiogenesis is a hypoxia-driven process (Carmeliet and Jain 2011, 
Quaegebeur et al 2011). PHDs have been described to drive angiogenesis 
and regulate perfusion in different organs as a means to increase oxygen 
delivery (Quaegebeur and Carmeliet 2010, Takeda et al 2011). Also, collateral 
flow and hence residual vascular perfusion determines stroke size both in 
mice and in patients (Shuaib et al 2011, Zhang et al 2010). Therefore, we 
explored whether PHD1 deficiency would protect against ischemia by 
affecting the brain vasculature and improving cerebral perfusion.  
Perfusion with FITC-conjugated dextran (unable to leak out of brain 
vessels given its molecular weight of 20,000 kDa) was used to assess the 
patency of cerebral vessels. Quantification showed a similar area of perfused 
vessels in the cortical area of (non-stroked) wild type versus PHD1-/- brains 
(Figure 5A-C). To explore whether PHD1 deficiency affects arteriogenesis in 
the brain, we stained (non-stroked) wild type and PHD1-/- brains for α-smooth 
muscle actin  (α-SMA), visualizing the larger conducting arterioles and 
arteries. This analysis did not reveal genotypic differences either (Figure 5D-
F).  
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Figure 5: The PHD1-/- brain does not show more vessel perfusion or more 
arterioles 
Representative images of WT (A) and PHD1-/- (B) frontal cortex after FITC-
dextran injection. Quantification of the FITC-dextran-positive area as 
percentage of the cortical area (reflecting vessel perfusion in the cortex) is 
shown in C (N=6-7, P=0.19). Representative images of α-SMA 
immunostaining, visualizing arterioles (yellow arrows), in WT (D) and PHD1-/- 
brains (E). Quantification of α-SMA positive area as percentage of total brain 
area is shown in F (N=4-5, P=0.67). Scale bar A,B: 200 µm; D,E: 500 µm.  
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Figure 6: The PHD1-/- brain does not show enhanced pial collateral 
circulation  
(A-B) Representative images of 3D vascular corrosion casting showing pial 
circulation in WT (A) and PHD1-/- brain hemispheres (B). Collaterals were 
counted per hemisphere (purple arrows). (C) Quantification of pial collaterals 
per hemisphere in WT versus PHD1-/- brains (N=3-4; P=0.60) 
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Since arteriogenesis is unaffected, it would seem less probable that 
the stroke area in the PHD1-/- brain receives more collateral blood flow at the 
time of the arterial occlusion. To exclude this with more certainty, we 
specifically imaged the pial collateral circulation, as these collaterals are 
known to contribute to collateral flow in the stroke area following pMCAO 
(Zhang et al 2010). After infusion of a resin, a three dimensional corrosion 
cast of the brain vasculature was made. We quantified the number of pial 
collaterals in one hemisphere, which mainly reflect the bridging arterioles 
between the anterior cerebral artery and the middle cerebral artery (Zhang et 
al 2010). This showed a similar number of pial collaterals in wild type and 
PHD1-/- brain (Figure 6A-C). 
These data indicate that PHD1 deficiency does not majorly affect the 
vasculature in the brain. Systemic erythropoietin (EPO) and hematocrit levels, 
which determine the oxygen carrying potential of the blood and might affect 
the infarct size by improving tissue oxygenation (Sakanaka et al 1998, Siren 
et al 2001), were already shown to be unaffected in PHD1-/- mice in a 
previous report (Aragones et al 2008). In conclusion, PHD1 deficiency does 
not protect against brain ischemia via improving oxygen delivery.  
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PHD1-/- NEURONS ARE PROTECTED AGAINST OXYGEN-NUTRIENT 
DEPRIVATION IN VITRO 
Given the lack of clear vascular changes in the PHD1-/- brain, we next 
hypothesized that PHD1 deficiency would confer neuroprotection by 
modulating intrinsic neuronal properties. We therefore assessed the effect of 
ischemia in cultured cortical neurons. We exposed cortical neurons (isolated 
from wild type and PHD1-/- E14.5-15.5 embryonic brains) after 7 days in 
culture to oxygen-nutrient deprivation for a 2 hour period. At this time, the 
cortical neurons have evolved into fully mature neurons, carrying features of 
adult neurons (Dotti et al 1988). In this period they are kept at 0.1% oxygen in 
medium lacking not only glucose but also glutamine and pyruvate, after which 
they were re-exposed to ambient air and nutrient-rich medium. This assay, 
often incorrectly referred to as oxygen-glucose deprivation (as it is a more 
global nutrient deprivation), has been extensively used in the literature as an in 
vitro model of ischemia to test the intrinsic protective properties of neurons 
against ischemia (Goldberg and Choi 1993). During the oxygen-nutrient 
deprivation period, energy homeostasis will be acutely challenged. A small 
fraction of neurons will undergo immediate necrotic death due to severe ATP 
depletion, whereas the majority will undergo a delayed apoptotic death 
(Meloni et al 2011). The latter event will even be further facilitated by the re-
exposure to oxygen and nutrients, which causes a surge in oxygen radicals, 
resulting in the so-called “reperfusion injury”.  
Cell death was measured 24 hours after the oxygen-nutrient 
deprivation injury by quantifying LDH release in the medium, a method often 
used to assess neuronal cell death in culture (Koh and Choi 1987). Whereas 
40% cell death was observed in wild type neurons, cell death was largely 
prevented in PHD1-/- neurons (Figure 7), almost approaching baseline cell 
death over 24 hours in the control normoxia condition, which was around 
15% and similar between the two genotypes (not shown).   
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Figure 7: PHD1-/- neurons are largely 
protected against oxygen-nutrient 
deprivation.  
Neuronal cell death measured as LDH 
release (% of maximal LDH release) 
over 24 hours after oxygen-nutrient 
deprivation in WT and PHD1-/- neurons 
(N=3, *P<0.05). 
 
 
 
 
 
To exclude that structural differences in the PHD1-/- embryos or 
different PHD1-/- neuronal culture features would contribute to this resilience 
against in vitro ischemia, we performed additional control experiments. 
Macroscopic inspection of embryos revealed that loss of PHD1 did not cause 
prominent developmental central nervous system defects. Nissl staining 
revealed a normal brain cytoarchitecture in PHD1-/- embryos (data not shown). 
In agreement, isolation from E14.5 PHD1-/- embryos yielded similar numbers 
of cortical neurons. These appeared morphologically normal, showed similar 
neurite arborization, established comparable numbers of synapses, and 
survived for normal periods comparable to wild type neurons (data not 
shown). There were also no genotypic differences in the fraction of 
contaminating non-neuronal cells (< 2%, determined by staining for GFAP, 
NG2 and Olig2).  
In order to exclude chronic compensatory changes due to constitutive 
absence of PHD1, we measured the transcript levels of PHD2, PHD3 or FIH in 
PHD1-/- neurons, which were no different than in their wild type counterparts 
(Figure 8A). These data are in accordance with the absence of induced 
expression of other PHD isoforms in PHD1-/- brains. Of importance, PHD2 and 
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PHD3 silencing (by means of lentiviral shRNA) did not confer protection 
against oxygen-nutrient deprivation, indicating a PHD1-specific effect, again 
in accordance with the PHD1 specific protection in the pMCAO model (Figure 
8B). 
 
 
Figure 8: The protective effect against oxygen-nutrient deprivation is 
PHD1-specific. 
(A) mRNA levels of PHD2 and PHD3 in isolated PHD1-/- neurons expressed as 
fold change relative to WT (N=3, P=0.66 for PHD2 mRNA, P=0.98 for PHD3 
mRNA). (B) Neuronal cell death measured as LDH release (% of maximal LDH 
release) over 24 hours after oxygen-nutrient deprivation in PHD2 silenced and 
PHD3 silenced cells compared to control (N=3, P=0.92 for shPHD2 vs ctrl), 
P=0.83 for shPHD3 vs ctrl). 
 
It has been established for a while that enhanced neurotrophin expression 
protects against a variety of stressors, among which ischemia (Ferenz et al 
2012, Klumpp et al 2006). Therefore, we quantified the expression of different 
neurotrophic factors and their receptors in cultured neurons. No statistical 
significant differences were observed between wild type and PHD1-/- neurons 
(table 1) 
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Table 1: Gene expression analysis of neurotrophic factors  
 
GENE WT NEURONS PHD1-/- NEURONS 
Bdnf 1.00 ± 0.12 0.87 ± 0.07 
Ngf 1.00 ± 0.12 0.88 ± 0.09 
Nt3 1.00 ± 0.14 0.93 ± 0.08 
p75 1.00 ± 0.09 0.87 ± 0.14 
TrkB 1.00 ± 0.08 0.97 ± 0.10 
TrkC 1.00 ± 0.14 0.95 ± 0.20 
Vegf-a 1.00 ± 0.11 1.11 ± 0.06 
Vegf-b 1.00 ± 0.03 0.88 ± 0.09 
Vegfr2 1.00 ± 0.15 0.81 ± 0.06 
 
Quantitative RT-PCR data of different neurotrophic factors and their receptors 
in WT and PHD1-/- neurons. Representative experiments of fold expression in 
the PHD1-/- neurons compared to WT neurons are shown (mean±SEM, N=3-4, 
P=ns). Bdnf: Brain-derived neurotrophic factor; Ngf: Nerve growth factor; Nt3: 
Neurotrophin 3; p75: p75 neurotrophin receptor; TrkB and TrkC: tyrosine 
receptor kinase B and C; Vegf-a and Vegf-b: vascular endothelial growth 
factor A and B; Vegfr2: Vascular endothelial growth factor 2. 
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PHD1 DEFICIENCY REPROGRAMS GLUCOSE METABOLISM IN NEURONS 
PHD1 deficiency has previously been shown to protect against ischemia in 
the muscle via altering its glucose metabolism (Aragones et al 2008). By 
reducing pyruvate entry into the mitochondria, PHD1-/- muscle fibers reduce 
their respiration rate and, as a consequence, produce less reactive oxygen 
species (ROS). In addition, glycolytic flux is increased, likely as a 
compensation to maintain sufficient ATP production. Hence, we next 
investigated whether a similar metabolic shift would explain the ischemia 
tolerance in PHD1-/- neurons. To explore glucose metabolism, we measured 
metabolic fluxes by incubating cultured neurons for 2 hours with a 
radioactively-labeled glucose tracer. Postulating that metabolic changes 
might account for the protective effect, all metabolic measurements were 
performed after neurons spent 7 days in culture, the same time that cultures 
are subjected to oxygen-nutrient deprivation.  
In sharp contrast to the metabolic phenotype of PHD1-/- muscle fibers, 
the glycolytic rate of PHD1-/- neurons, quantified by the production of 3H2O 
after supplementation with [5-3H]-glucose, was reduced – not increased – by 
25.4 ± 4.2% (nmol glucose/h/106 cells: 285 ± 85 for wild type versus 199 ± 54 
for PHD1-/- neurons, N=8, *P<0.05, Figure 9A,B). Measuring 14CO2 release 
after incubation with [6-14C]-glucose showed a 23 ± 3.4% reduction in the 
glucose oxidation rate in PHD1-/- neurons (pmol glucose/h/106 cells: 1425 ± 
176 for wild type versus 1116 ± 179 for PHD1-/- neurons, N=4, ***P<0.001, 
Figure 9C,D). To discriminate whether this was due to a reduced entry of 
glycolytic intermediates (as a result from the reduction in glycolytic flux) or to 
an impaired mitochondrial activity, we also supplied [U-14C]-lactate, which can 
be converted to [U-14C]-pyruvate, enter the TCA cycle and become oxidized in 
the same way as [6-14C]-glucose. These measurements showed that [U-14C]-
lactate oxidation was similar for both genotypes (pmol lactate/h/106 cells: 
6327 ± 178 for wild type versus 6564 ± 596 for PHD1-/- neurons; N=3; P=0.7), 
indicating that a reduced entry of glycolytic intermediates rather than a 
mitochondrial defect caused the reduced glucose oxidation.  
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Figure 9 PHD1-/- neurons reduce their glycolytic flux and glucose 
oxidation rate. 
(A) Schematic overview of glycolytic flux measurements via incubation of cells 
with tracer amounts of 5-3H-glucose. The resulting 3H2O release during 
glycolysis reflects the rate of glycolysis. (B) Representative experiment of 
relative (%) change of glycolytic flux measured over 2 hrs in PHD1-/- neurons 
compared to WT neurons (N=4, **P<0.01). (C) Schematic overview of glucose 
oxidation rate measurements via incubation of cells with tracer amounts of 6-
14C-glucose. 14CO2 will be released through oxidation of TCA intermediates in 
the TCA cycle, reflecting the rate of glucose oxidation. (D) Representative 
experiment of relative (%) change of glucose oxidation measured over 2 hrs in 
PHD1-/- neurons compared to WT neurons (N=3, *P<0.05). 
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The reduced glucose oxidation was also not due to a decrease in the 
number of mitochondria as determined by PCR analysis of mitochondrial 
(mtDNA) versus genomic (gDNA) DNA (ratio gDNA/mitoDNA: 1.595 ± 0.065 for 
WT versus 1.565 ± 0.032 for PHD1-/- neurons; N=3; P=0.7). In line with this, 
mitochondrial density as analyzed by staining of neurons for the mitochondrial 
marker TOMM20 revealed no genotypic differences (Figure 10A-G).  
Also at the functional level, PHD1-/- mitochondria behaved similarly as 
their WT counterparts: the oxygen consumption rate (OCR), measured using 
the Seahorse extracellular flux analyzer, was not altered in PHD1-/- neurons 
(Figure 11B) (this apparent paradox with the reduced glucose oxidation rate 
will be explained below). Besides baseline OCR (OCRBAS), we also measured 
OCR coupled to ATP synthesis (OCRATP; sensitive to oligomycin) and maximal 
respiration (OCRMAX; induced by the uncoupler DNP) (Figure 11A). PHD1 
deficiency did not affect these bioenergetic features of the mitochondria either 
(Figure 11C). 
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Figure 10: PDH1-/- neurons show a similar number of mitochondria  
(A-F) Representative images from TOMM20 and MAP2 immunostaining, 
visualizing mitochondria and neurons respectively, in WT (A-C) and PHD1-/- 
neurons (D-F). Quantification of mitochondrial area per cell (i.e. MAP2 positive 
area) is shown in G (N=3, P=0.87). 
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Figure 11: PHD1-/- mitochondria show similar bioenergetics features  
(A) The Seahorse extracellular flux analyzer allows the measurement of 
different bioenergetics parameters by sequential injection of different 
mitochondrial compounds. Antimycin A injection blocks complex III and 
allows the calculation of baseline mitochondrial respiration (OCRBAS). 
Oligomycin injection blocks ATP synthase and allows the measurement of 
respiration coupled to ATP synthesis (OCRATP). Maximal respiration (OCRMAX) 
is induced by the uncoupler DNP. (B) Representative experiment of OCRBAS in 
WT and PHD1-/- neurons (N=8-9; P=0.5). (C) Relative change of OCRATP and 
OCRMAX compared to OCRBAS (dotted line) in WT and PHD1
-/- neurons (N=3; 
P=0.65 for OCRMAX and P=0.94 for OCRATP). 
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Overall, in sharp contrast with the metabolic phenotype in the PHD1 
deficient muscle, PHD1-/- neurons do not show a shift from oxidative to 
anaerobic metabolism, but maintain their mitochondrial metabolism and even 
lower their glycolytic flux. Notably, gene expression analysis could not link the 
reduced glycolysis to transcriptional changes in metabolic enzyme expression 
(table 2).  
 
 
Table 2: Gene expression analysis of glycolytic enzymes  
 
GENE WT NEURONS PHD1-/- NEURONS 
Glut-1 1.00 ± 0.02 0.92 ± 0.05 
Glut-3 1.00 ± 0.20 0.93 ± 0.05 
Hk1 1.00 ± 0.05 1.11 ± 0.08 
Pfk1 1.00 ± 0.20 0.80 ± 0.09 
Pfkfb3 1.00 ± 0.09 1.02 ± 0.10 
Gapdh 1.00 ± 0.09 0.92 ± 0.09 
Pgam2 1.00 ± 0.20 1.30 ± 0.26 
enolase 1.00 ± 0.07 1.24 ± 0.11 
Ldh-a 1.00 ± 0.06 0.93 ± 0.13 
Pdk1 1.00 ± 0.10 0.95 ± 0.08 
Pdk4 1.00 ± 0.03 1.07 ± 0.04 
 
Quantitative RT-PCR data of different glycolytic genes in WT and PHD1-/- 
neurons in baseline conditions. Representative experiments of fold expression 
in the PHD1-/- neurons compared to WT neurons are shown (mean± SEM, 
n=3-4, p=ns). Glut1: glucose transporter 1; Hk1: hexokinase; Pfk1: 
phosphofructokinase; Pfkfb3: 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase; Gapdh: glyceraldehyde-3-phosphate dehydrogenase; Pgam2: 
phosphoglycerate mutase 2; Ldh-a: lactate dehydrogenase a; Pdk1: pyruvate 
dehydrogenase kinase, isoform 1.  
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PHD1-/- NEURONS SHOW AN ENHANCED FLUX THROUGH THE OXPPP 
These observed metabolic changes taught us that PHD1 deficiency has 
diverging cell-type specific effects on cellular metabolism. However, they did 
not provide an immediate explanation as to why PHD1-/- neurons are 
protected against ischemia. Previous work pointed out that glycolytic flux in 
neurons is kept at a low rate to enable a sufficient flux of glucose through the 
oxidative pentose phosphate pathway (oxPPP) (see also chapter I) (Herrero-
Mendez et al 2009). The PPP is an alternative route for glucose-6-phosphate 
besides glycolysis. The oxPPP refers to the oxidative branch of this pathway 
where glucose oxidation converts [NADP+] to [NADPH]. NADPH produced by 
the oxPPP was recently shown to be of vital importance in replenishing the 
pool of reduced glutathione (GSH) and maintaining redox homeostasis in 
neurons (Herrero-Mendez et al 2009).  
Given this reciprocal regulation of glycolysis and the oxPPP, we hypothesized 
that the reduced glycolytic flux was part of glucose rerouting towards the 
oxPPP. To investigate whether PHD1 affects the oxPPP, we measured 14CO2 
production upon incubation with [6-14C]-glucose (producing 14CO2 only in the 
TCA cycle) or [1-14C]-glucose (producing 14CO2 in both the TCA cycle and 
PPP) and subtracted the [6-14C]-glucose flux from the [1-14C]-glucose flux. 
This analysis revealed a more than 2-fold induction in the absolute flux levels 
of the oxPPP in PHD1-/- neurons (pmol glucose/h/106 cells: 190 ± 44 for wild 
type versus 467 ± 51 for PHD1-/- neurons; N=4; P<0.01; Figure 12A,B)†. When 
calculating the relative flux by correcting for the level of the glycolytic flux 
(reflecting the contribution of the oxPPP to glucose metabolism), the relative 
oxPPP flux was even increased 8-fold (Figure 12C). These findings suggested 
that PHD1 deficiency shifts glucose from glycolysis towards the oxPPP.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  †	  Note that the absolute PPP flux levels in (B) are lower than generally reported in the 
literature. This is probably due to the usage of an open-air system (increasing the 
escape of 14CO2 during the incubation).	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Figure 12: Enhanced oxPPP flux in the PHD1-/- neurons. 
(A) Schematic overview of oxPPP-flux measurements. Incubation with 1-14C-
glucose (in green) results in 14CO2 formation in the oxPPP but also in the TCA 
cycle whereas 6-14C-glucose (blue) incubation will result in 14CO2 release only 
in the TCA. Therefore, the 6-14C-glucose flux subtracted from the 1-14C-
glucose flux reflects the flux through the oxPPP. (B) Relative (%) change of 
absolute oxPPP flux in PHD1-/- neurons compared to WT neurons (N=4; 
**P<0.01). (C) Relative oxPPP flux in WT and PHD1-/- neurons (N=4).  
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PHD1 DEFICIENCY IMPROVES ROS SCAVENGING CAPACITY IN NEURONS 
Glutathione peroxidase detoxifies H2O2 to H2O by converting reduced 
glutathione (GSH) into its oxidized form (GSSG). GSH is then regenerated 
through oxidation of [NADPH] by glutathione reductase. The increased oxPPP 
flux would thus imply an improved scavenging capacity of H2O2 and oxygen 
radicals in general. To explore this possibility, we exposed neurons, labeled 
with CM-H2DCF (a dye measuring ROS levels), to 100 µM H2O2 and measured 
H2O2 levels over time. In this way, the detoxification rate of H2O2 and hence 
the recycling rate of glutathione reduction can be assessed. Compared to WT 
neurons, PHD1-/- neurons showed a less steep increase in CM-H2DCF 
fluorescence intensity over time (Figure 13A), implying accelerated 
detoxification of the administered H2O2 molecules.  
Next, we investigated whether the enhanced oxPPP flux, via 
accelerating the glutathione recycling, was responsible for the improved ROS 
scavenging capacity. Therefore, we blocked the oxPPP flux by silencing 
glucose-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme 
of the oxPPP flux (Figure 13B). Using a lentiviral shRNA against G6PD, a 
knockdown efficiency of 80% was reached, and the oxPPP flux in PHD1-/- 
neurons was nullified (Figure 13C). G6PD silencing deteriorated the 
scavenging capacity of PHD1-/- neurons (Figure 13D), suggesting that their 
improved ROS scavenging capacity is, at least partially, dependent on their 
increase in oxPPP flux. As G6PD silenced PHD1-/- neurons maintained a 
tendency of a slight improved scavenging potential, it is possible that PHD1 
deficiency enables other (compensatory) mechanisms allowing ROS 
scavenging upon PPP blockade. Gene expression analysis of various anti-
oxidant enzymes did not show enhanced expression of the most prevalent 
anti-oxidant-enzymes in neurons (table 3).  
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Figure 13: PHD1 deficiency and oxPPP flux improve the scavenging 
capacity of oxygen radicals in neurons.  
(A) Representative time course of the increase in CM-H2DCF fluorescence 
depicting ROS levels over time after administration of H2O2 in WT and PHD1
-/- 
neurons (N=6; ****P<0.0001, two-way ANOVA). a.u.: arbitrary units. (B) 
Scheme showing consequences of silencing G6PD (shG6PD): inhibition of 
PPP flux leads to a lower glutathione reduction rate and hence less 
detoxification of H2O2. (C) oxPPP flux in control and G6PD silenced PHD1
-/- 
neurons (N=3; P=0.056). (D) Relative increase in CM-H2DCF fluorescence 20 
minutes after H2O2 administration to WT and PHD1
-/- neurons (N=3; *P<0.05 
for WT versus PHD1-/- neurons; P=0.47 for G6PD silenced WT and PHD1-/- 
neurons ). 
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Table 3: Gene expression analysis of anti-oxidant enzymes  
 
GENE WT NEURONS PHD1-/- NEURONS 
GCLC 1.00 ± 0.10 0.84 ± 0.04 
Gpx1 1.00 ± 0.04 0.98 ± 0.09 
Gpx4 1.00 ± 0.04 1.08 ± 0.02 
Prdx1 1.00 ± 0.05 0.99 ± 0.10 
Prdx3 1.00 ± 0.14 1.21 ± 0.25 
Prdx4 1.00 ± 0.09 1.26 ± 0.16 
Sesn1 1.00 ± 0.02 0.94 ± 0.08 
Sesn2 1.00 ± 0.11 1.26 ± 0.04 
SOD1 1.00 ± 0.07 0.93 ± 0.14 
SOD2 1.00 ± 0.10 0.86 ± 0.11 
 
Quantitative RT-PCR data of different anti-oxidant genes in WT and PHD1-/- 
neurons in baseline conditions. Representative experiments of fold expression 
in the PHD1-/- neurons compared to wild type (WT) neurons are shown (mean± 
SEM, N=3-6, P=ns). GCLC: glutamate-cystein ligase catalytic subunit; Gpx: 
glutathione peroxidase; Prdx: peroxiredoxin; Sesn: sestrin; SOD: superoxide 
dismutase.  
 
 
PHD1 DEFICIENCY COUNTERACTS HYPOXIC METABOLISM IN NEURONS 
In various cell types, it is firmly established that hypoxia induces a HIF-1α 
mediated increase in glycolytic flux (see chapter I). Also in cultured neurons, 
we observed an elevated glycolytic flux upon hypoxic exposure. In line with 
this, HIF-1 protein levels and mRNA levels of various glycolytic genes were 
upregulated under these circumstances (data not shown). Even though PHD1-
/- neurons also responded to hypoxia by increasing their glycolytic flux, the 
glycolytic flux rate remained lower in hypoxic PHD1-/- than in WT neurons 
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(Figure 14A). 
Given the reciprocal regulation of glycolysis and oxPPP, we questioned 
how hypoxia would affect the oxPPP flux. Strikingly, hypoxia nullified the 
oxPPP flux in wild type neurons. PHD1-/- neurons however were able to 
maintain a measurable oxPPP flux, although it was smaller than in normoxic 
conditions (Figure 14B). These data suggest that PHD1 deficiency attenuates 
the hypoxia-induced metabolic shift in which glycolysis increases at the 
expense of the oxPPP flux. By reprogramming glucose metabolism and 
maintaining a oxPPP flux, PHD1 deficiency ensures redox homeostasis, 
especially during ischemic challenges. 
 
 
Figure 14: PHD1 deficiency attenuates hypoxia-induced metabolic 
changes in neurons 
(A) Representative experiment of relative (%) change of glycolytic flux in 
PHD1-/- neurons compared to WT neurons in normoxic and hypoxic conditions 
(0.1% O2 for 2 hours) (N=4; *P<0.05, **P<0.01 and ***P<0.001). (B) Relative 
(%) change of oxidative PPP flux in PHD1-/- neurons compared to WT neurons 
in normoxic and hypoxic conditions (0.1% O2 for 2 hours) (N=3, *P<0.05).  
 
 
 
WT PHD1-/- WT PHD1-/-
0
1000
2000
3000
4000
nm
ol
 g
lu
co
se
/h
/1
06
 c
el
ls
normoxia hypoxia
***
*
WT PHD1-/- WT PHD1-/-
0
500
1000
1500
pm
ol
 g
lu
co
se
/h
/1
06
 c
el
ls
normoxia hypoxia
*
*
A B Pentose-phosphate pathwayGlycolysis
	   92 
PHD1-/- NEURONS OXIDIZE MORE GLUTAMINE 
So far, we described that a reduction of glycolysis was linked to an increase 
in PPP and to a decreased oxidation of glucose in the mitochondria. At first 
sight, it might be expected that a reduction in glucose oxidation would 
threaten the energy homeostasis and jeopardize neuronal survival. However, 
given the comparable oxygen consumption rates in wild type and PHD1-/- 
neurons, we hypothesized that as compensation, oxidation of alternative 
substrates would be enhanced. Previous studies indeed established that 
neurons oxidize not only glucose, but also lactate and glutamine, provided by 
their neighboring cells (Mergenthaler et al 2013).  
As mentioned earlier, the oxidation of lactate was unaffected in PHD1-/- 
neurons. Glutamine is another energy substrate that after conversion first to 
glutamate by glutaminases (GLS1 and GLS2) and, thereafter, to α-
ketoglutarate (αKG) by glutamate dehydrogenase (Glud), will enter the TCA 
cycle. Here it is subjected to different oxidation steps that produce CO2 and 
generate energy producing NADH molecules. To determine whether glutamine 
was oxidized differently in PHD1-/- neurons, we incubated cells with [U-14C] 
glutamine and monitored the release of 14CO2. These measurements revealed 
that glutamine oxidation rates were modestly enhanced in PHD1-/- neurons 
(pmol glutamine/h/106 cells: 1,144 ± 73 for WT versus 1,564 ± 88 for PHD1-/- 
neurons; N=3; *P<0.05). Gene expression analysis of enzymes involved in 
glutamine metabolism showed a modest increase in Gls2 mRNA levels in 
PHD1-/- neurons (relative mRNA expression: 1.00 ± 0.05 in WT neurons versus 
1.57 ± 0.14 for PHD1-/- neurons; N=3-4; **P<0.01) (table 4).  
Taken together, these data suggest that the decrease in ATP 
production due to the reduction of glucose oxidation was compensated by an 
enhanced production of ATP resulting from increased glutamine oxidation. 
Indeed, PHD1 deficiency did not alter the energy charge balance ([ATP] + ½ 
[ADP]) / ([ATP] + [ADP] + [AMP]) (0.95 ± 0.001 for WT versus 0.95 ± 0.001 for 
PHD1-/- neurons; N=4; P=0.72), indicating that PHD1-/- neurons were not in 
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energy distress.  
 
Table 4: Gene expression analysis of glutamine metabolism  
 
GENE WT NEURONS PHD1-/- NEURONS 
Gls1 1.00 ± 0.11 1.01 ± 0.05 
Gls2 1.00 ± 0.05     1.57 ± 0.14 ** 
Glud 1.00 ± 0.06 0.92 ± 0.08 
Quantitative RT-PCR analysis (representative experiment) of the expression of 
different genes involved in glutamine metabolism in WT and PHD1-/- neurons 
(baseline conditions). Data are expressed relative to WT neurons (mean±SEM, 
N=3-4, **P<0.01). Gls: glutaminase; Glud: glutamate dehydrogenase. 
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GLYCOGEN AS A POSSIBLE SOURCE OF ENERGY IN PHD1-/- NEURONS DURING 
ISCHEMIA 
Our observations so far demonstrated that loss of PHD1 enhanced neuronal 
anti-oxidant defense mechanisms. We next questioned whether besides 
enhanced ROS scavenging capacity (which would protect neurons especially 
during the reperfusion period), PHD1-/- neurons also possess alternative 
mechanisms to counter ATP depletion during oxygen-nutrient deprivation. To 
address this possibility, we deprived WT and PHD1-/- neurons for 8 hours from 
oxygen (0.1% O2) and nutrients (glucose, glutamine and pyruvate) and 
monitored their energy charge. While in WT neurons the energy charge 
declined more than 50% after 8 hours, indicating severe energetic stress, loss 
of PHD1 enabled a better maintenance of the energy charge during oxygen-
nutrient deprivation (Figure 15). Thus, PHD1-/- neurons are more resistant to 
prolonged starvation.  
 
 
 
 
 
 
 
 
 
 
Figure 15: PHD1 deficiency improves energy charge maintenance during 
prolonged oxygen-nutrient deprivation 
Energy charge measured in WT and PHD1-/- neurons in normoxic conditions 
and after 8 hours of oxygen-nutrient deprivation (OND) (for normoxia: N=3; 
P=0.7; for 8 hrs OND: N=3; *P<0.05). 
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These data strongly suggests that PHD1-/- neurons possess an alternative 
energy store that can be recruited whenever extracellular nutrients are 
lacking. Increased autophagy would theoretically be an alternative protective 
mechanism in nutrient starvation. However, numerous papers have indicated 
that in cultured neurons the activation of the autophagy pathway is 
contributive to neuronal cell death rather than being protective (Degterev et al 
2005, Shi et al 2012, Wen et al 2008).  
The most plausible internal energy store would be glycogen, even 
though it has been debated whether or not neurons could store glycogen 
(DiNuzzo et al 2011). A recent report showed that neurons do accumulate 
limited stores of glycogen, which can be utilized during ischemia (Saez et al 
2014). We used the Periodic Acid Schaff (PAS) staining to assess the 
glycogen content. Initial data show that WT neurons indeed contained few 
and faint PAS-positive granules in their cytoplasm (Figure 16A-C), whereas 
PHD1-/- neurons showed more PAS-positive granules with higher staining 
intensity (Figure 16D-F).  
 
 
 
 
 
 
 
 
 
 
Figure 16: PHD1-/- neurons have a higher glycogen content.  
Representative images of a PAS-staining in WT and PHD1-/- neurons. (A-C) 
WT neurons containing some faint PAS-positive granules in their cytoplasm. 
(D-F) PHD1-/- neurons showing more and larger PAS-positive granules with 
higher staining intensity (Figure 17D-F).  
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ISCHEMIC PROTECTION IN PHD1-/- NEURONS IS HIF-INDEPENDENT  
HIF-1α and HIF-2α are the two best-characterized hydroxylation targets of 
PHDs. In different organs and tissues, HIF-1α and/or HIF-2α were shown to 
mediate the effects of PHD deficiency, even though HIF-independent effects 
have been increasingly recognized (Quaegebeur and Carmeliet 2010, Wong et 
al 2011). In normoxic PHD1-/- neurons, given the lack of hydroxylation activity 
by PHD1, one would expect increased levels of HIF-1α and HIF-2α. 
Immunoblotting showed that levels of HIF-1α were not elevated in normoxic 
PHD1-/- neurons nor in PHD1-/- brain (Figure 17A,B). In repeated attempts, 
HIF-2α protein could not be visualized in normoxic conditions.  
Additionally, we explored the potential involvement of HIF-1α and HIF-
2α by assessing the effect of HIF-1α and HIF-2α silencing on PHD1 deficient 
neuronal protection. Silencing of HIF-1α via a lentiviral vector expressing a 
shRNA against HIF-1α did not abolish the protection against oxygen-nutrient 
deprivation by PHD1 deficiency, nor did a shRNA against HIF-2α (Figure 17C). 
Interestingly, lowering HIF-1α levels in in vitro ischemia even attenuated 
neuronal cell death both in wild type and PHD1-/- neurons. Taken together, 
these data point towards a HIF-independent mechanism. 
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Figure 17: HIF-1α levels are not induced in PHD1-/- neurons and neither 
HIF-1α or HIF-2α explain the ischemic protection 
(A-B) Representative western blots showing protein levels of HIF-1α in WT 
and PHD1-/- normoxic cortical neurons (A) and normoxic brains (B). (C) 
Representative experiment showing neuronal cell death measured as LDH 
release (% of maximal LDH release) over 24 hours after oxygen-nutrient 
deprivation in WT and PHD1-/- neurons upon HIF-1α and HIF-2α silencing 
(N=5-6, **P<0.01, ***P<0.001). 
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INTRACEREBROVENTRICULAR DELIVERY OF ANTI-PHD1-DIRECTED 
OLIGONUCLEOTIDES PROTECTS AGAINST BRAIN ISCHEMIA 
We intended to explore the translation potential of PHD1 inhibition in ischemic 
stroke. PHD1 inhibition might be an attractive target for different reasons. First 
of all, genetic deletion of PHD1 results in a pronounced protection against 
brain ischemia. Additionally and of paramount importance, PHD1 loss does 
not result in major deficits in mice, as was shown in previous studies 
(Aragones et al 2008, Schneider et al 2009, Tambuwala et al 2010). This 
suggests that PHD1-specific inhibitors might have a more favorable side-
effect profile than the available aspecific PHD inhibitors. Since at the initiation 
of this study no specific PHD1 inhibitor was available, we turned to the 
possibility of delivering antisense oligonucleotides (ASOs). The 
oligonucleotides were designed and generated by Isis Pharmaceuticals as 
previously described (Bennett and Swayze 2010). A library of ASOs was 
screened for targeting murine PHD1 and three different ASOs were selected 
for further research (by Isis Pharmaceuticals). Out of these three, we selected 
the ASO with the highest knockdown efficiency and specificity to use in our in 
vivo studies.  
First, we tested the selected ASO in vitro. After incubation of cultured 
cortical neurons with 0.5 µM** of the anti-PHD1 ASO for 5 days, a knockdown 
efficiency of 85% was obtained. We additionally determined PHD2 and PHD3 
mRNA levels in these cultures, which remained unaffected (Figure 18A). This 
confirmed the efficacy and specificity for PHD1 of this ASO. 
In a next step, we investigated the feasibility of in vivo delivery of ASOs. 
Since the blood-brain barrier is not permeable for ASOs (Broaddus et al 2000, 
Cossum et al 1993, Smith et al 2006), we chose intracerebroventricular 
delivery via osmotic pumps as previously described (Storkebaum et al 2005). 
The ASOs were continuously infused over the course of 2 weeks at a rate of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  **	  This concentration was chosen based on advice from Isis Pharmaceuticals and 
after a dose-response experiment identifying 0.5 µM as the concentration with the 
highest PHD1 knockdown efficiency and specificity.	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75 µg/day, a dose which was based on the advice of Isis Pharmaceuticals. 
The animals tolerated this treatment well and no premature deaths were 
noted. After these 2 weeks, brains were harvested and PHD1 mRNA levels 
were assessed. This analysis showed that intracerebroventricular delivery of 
anti-PHD1 ASOs lowered PHD1 brain mRNA levels to 50% of control treated 
animals (Figure 18B).  
 
 
Figure 18: Anti-PHD1 oligonucleotides lower PHD1 levels in cultured 
cortical neurons and in brain tissue 
(A) mRNA expression levels of PHD1, PHD2 and PHD3 in neuronal cultures 
incubated with anti-PHD1 oligonucleotides (0.5 µM) for 5 days, relative to 
levels in neuronal cultures incubated with control oligonucleotides (0.5 µM). 
(B) mRNA expression levels of PHD1 in brain homogenates from control 
treated mice and anti-PHD1 oligonucleotide treated mice (N=4-5; 
****P<0.0001). 
 
Given the successful knockdown of PHD1 in the brain, we tested the 
effect of ASO delivery on brain ischemia. Mice treated for 2 weeks with anti-
PHD1 ASOs underwent a permanent ligation of their middle cerebral artery 
and infarct size was assessed 24 hours later. Mice with intracerebroventricular 
delivery of saline or of control ASOs were used as two control groups. This 
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control ASO was directed against human huntingtin mRNA and was 
chemically modified to prevent any RNase H-mediated effects (personal 
communication with Isis Pharmaceuticals). Infarct size analysis showed a 
50% reduction in stroke lesion upon treatment with the anti-PHD1 ASOs 
(Figure 19A-J). Of importance, no difference in stroke size was observed 
between the saline and control ASO group, demonstrating that injection of an 
oligonucleotide per se did not cause additional effects that would influence 
stroke outcome.  
 
 
sa
lin
e
ctr
l o
lig
o
PH
D1
 ol
igo
0
2
4
6
8
st
ro
ke
 a
re
a 
(%
 o
f t
ot
al
 a
re
a) **
***
Saline control oligo anti-PHD1 oligo
A D G
J
EB
C F I
H
	   101 
 
Figure 19: PHD1 knockdown by anti-PHD1 oligonucleotides reduces the 
infarct size after pMCAO 
Representative brain slices after TTC staining, delineating the infarct zone as 
unstained area (white), from control mice receiving saline (A-C), control mice 
receiving human control oligonucleotides (D-F) and mice receiving anti-PHD1 
directed oligonucleotides (G-I), 24 hours after pMCAO. Quantification of the 
stroke area as percentage of the total bihemispheric area is shown in J (N=8 
for the saline group, N=5 for the control oligo group, N=9 for the anti-PHD1 
oligo group, **p<0.01 for control oligo versus anti-PHD1 oligo and ***p<0.001 
for saline versus anti-PHD1 oligo). Scale bar: 1 mm. 
 
 
Future research will have to point out whether PHD1 inhibition would also be 
a valid neuroprotective target when initiated after the onset of the stroke. The 
development and characterization of selective (preferably BBB-permeable) 
PHD1 inhibitors will be crucial in shaping clinical indications for PHD1 
inhibition and directing further studies. 
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PHD1 DEFICIENCY ATTENUATES NEURODEGENERATION IN A MOUSE MODEL 
OF ALS 
Energy depletion and oxidative stress are common players not only in acute 
ischemic stroke but also in neurodegenerative conditions with a more chronic 
disease course. We therefore hypothesized that PHD1 deficiency might also 
be beneficial in neurodegenerative disorders such as Alzheimer’s disease, 
Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s 
disease. We decided to focus our initial exploration on ALS (a 
neurodegenerative disease characterized by predominant degeneration of 
motorneurons). Next to Alzheimer’s disease, ALS is a neurodegenerative 
disorder with the strongest evidence that vascular deficits (e.g. impaired 
angiogenic responses, disregulation of vasomotor responses, BBB leakiness, 
…) and subsequent hypoxic events are majorly implicated in disease 
pathogenesis (Quaegebeur and Carmeliet 2010). We intercrossed PHD1-/- 
mice with SOD1G93A mice, a disease model for ALS based on overexpression 
of a human mutation in SOD1. This mutation is believed to result in 
degeneration of motorneurons via a gain-of-function mechanism. We 
compared paralysis onset (as defined by failed performance on the rotarod) 
and survival between PHD1-/- SOD1G93A and PHD1+/+ SOD1G93A littermates 
(females only). PHD1+/+ SOD1G93A mice lived on average 132 days, whereas 
PHD1-/- SOD1G93A mice were found to have an extended life span of, on 
average, 15 days (PHD1+/+ SOD1G93A mice: 132±2 days, N=16; PHD1-/- 
SOD1G93A mice: 147±6 days, N=11; P<0.01; Figure 20A). PHD1 deficiency also 
resulted in a delay in paralysis onset, even though this effect was less 
pronounced than the effect on survival (PHD1+/+ SOD1G93A mice: 123±2 days, 
n=15; PHD1-/- SOD1G93A mice: 132±5 days, N=11; P<0.05; Figure 20B). 
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Figure 20: PHD1 deficiency has a beneficial effect on survival and motor 
performance of SOD1G93A  mice 
(A) Kaplan-Meier curve showing probability of survival over time in PHD1-/- 
SOD1G93A  (blue) and PHD1+/+ SOD1G93A littermates (grey). Median survival is 
144 days for PHD1-/- SOD1G93A   mice (N=11) and 131.5 days for PHD1+/+ 
SOD1G93A mice (N=16) (Log-Rank test P<0.001). (B) Kaplan-Meier curve 
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showing probability of paralysis onset (defined as rotarod failure) over time in 
PHD1-/- SOD1G93A  (blue) and PHD1+/+ SOD1G93A littermates (grey). Median 
paralysis onset is 133 days for PHD1-/- SOD1G93A   (N=11) and 123 days for 
PHD1+/+ SOD1G93A (N=15) (Log-Rank test P<0.05). (C) Disease duration 
(defined as the interval between rotarod failure and survival) in PHD1+/+ 
SOD1G93A (grey) and PHD1-/- SOD1G93A  (blue) littermates (N=11 for PHD1-/- 
SOD1G93A   and N =15 PHD1+/+ SOD1G93A littermates; P=0.12) 
 
 
The larger effect on survival than on disease onset also implicates that 
PHD1 deficiency attenuated disease progression, which is of importance from 
a therapeutic perspective: PHD1-/- SOD1G93A mice showed a trend of a 60% 
increase in their disease duration (PHD1+/+ SOD1G93A mice: 10±1 days, N=14; 
PHD1-/- SOD1G93A mice: 16±2 days, N=11; P=0.12; Figure 21C). 
Our observation that genetic deletion of PHD1 has a beneficial effect on 
the disease course in an ALS mouse model might be a paradigm for PHD1 
inhibition in neurodegenerative disorders. Whether metabolic changes in 
motorneurons underlie the protective effect, whether anti-PHD1 
oligonucleotides can phenocopy the beneficial effect of genetic deletion, and 
whether PHD1 inhibition would be a valuable therapy for other 
neurodegenerative disorders, remain outstanding questions.  
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Chapter V  
 
DISCUSSION 
 
 
 
The primary finding of this study is that deletion of the oxygen sensor PHD1 
largely prevents brain ischemia following ligation of the middle cerebral artery 
in mice. This was not due to vascular alterations in the PHD1 deficient brain; 
instead neurons lacking PHD1 rewire their metabolism, which enables them to 
tolerate energy depletion and oxidative stress. In addition, we show that acute 
inhibition of PHD1 by oligonucleotide-mediated silencing mimics the 
protective effect of genetic deletion in ischemic stroke. This is - to the best of 
my knowledge - the first preclinical stroke study in which the effect of acute 
pharmacological inhibition of a single PHD isoform was investigated.  
 
1 GENETIC DELETION OF PHD1 IN BRAIN AND NEURONS PROTECTS 
AGAINST ACUTE ISCHEMIC STROKE  
There is ample genetic and pharmacological evidence for a protective role of 
PHD inhibition in ischemic disorders. However, the current PHD inhibitors 
have an unfavorable side effect profile due to their lack in specificity. 
Therefore, there is a compelling need for a more profound understanding of 
the isoform-specific roles and underlying molecular mechanisms in different 
organs before PHD inhibition will be translatable into a valid and clinically 
applicable therapeutic strategy.  
In this study, we reported that genetic deletion of PHD1 is protective 
against brain ischemia. This protective effect was reflected in a 70% smaller 
infarct size 24 hours after permanent ligation of the middle cerebral artery and 
was observed in two different mouse strains. Of importance, loss of PHD1 
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nearly completely prevented the functional sensorimotor deficits after stroke, 
an observation that remained over a prolonged period of time. The stroke size 
was not affected by PHD2 or PHD3 deficiency, indicating that, in the 
condition of permanent brain ischemia, PHD1 is the main oxygen sensor. Two 
recent studies reported however a beneficial effect of PHD2 deficiency in 
stroke, albeit in another, transient, model of cerebral ischemia. Neuron-
specific PHD2 knockout mice (by using CAMKII cre mice) were protected 
against cell death after transient cerebral ischemia (Kunze et al 2012) and 
heterozygous deficient PHD2 mice showed a trend of reduced infarct size 
after transient middle cerebral artery occlusion (tMCAO) (Chen et al 2012).  
Several reasons could possibly reconcile these reports with our 
observations that mice with a neural-specific deletion of PHD2 (by using 
Nestin Cre PHD2lox/lox mice, deleting PHD2 in neurons but also in glia) are not 
protected against stroke. First of all, transient occlusion with subsequent 
reperfusion is believed to involve other cellular and biochemical events 
preceding neuronal death than permanent ischemia. This jeopardizes the 
comparison of the effects in these two models (Hossmann 2012). Also, 
imaging, molecular and biochemical studies showed differences in the 
temporal evolution of penumbral and necrotic tissue in transient MCAO versus 
permanent MCAO. After permanent ligation of the middle cerebral artery, the 
final ischemic lesion can be determined 24 hours later (Hata et al 2000a), 
whereas the evolution after transient occlusion is more protracted with the 
ischemic lesion being final only after 3 days (Hata et al 2000b). In this regard, 
one could criticize the 24-hour time point used in the Kunze and the Chen 
study to assess infarct size (Chen et al 2012, Kunze et al 2012), since at this 
point the evolution of the ischemic lesion would still be incomplete (Hata et al 
2000b). 
Secondly, all three studies used different approaches to genetically 
silence PHD2: whereas neuron-specific deletion of PHD2 had a substantial 
effect on brain ischemia (Kunze et al 2012), heterozygous deficiency caused 
only a trend of reduced infarct size (Chen et al 2012), while neural-specific 
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PHD2 deletion in our study did not yield any difference. This underscores 
once more the cell-type specific (Nestin Cre versus CamKII cre) and dose-
dependent effects of PHDs. Finally, the study showing a partial protection by 
heterozygous PHD2 deficiency also reported a similar trend in PHD1-/- mice 
(Chen et al 2012). An important remark here is that this study used PHD1-/- 
mice in a mixed Swiss/129S6 background as compared to a pure 129S6 and 
C57/Bl6 background in our study, which might have modified the results. 
Since a strain-specific vulnerability is widely recognized in the field of 
experimental stroke, the usage of pure background strains is essential (Fujii et 
al 1997). From these studies it is unclear which mechanism is explanatory for 
the protective effect of PHD2 deficiency. In one study, PHD2 deficient mice 
showed a more rapid restoration of blood flow after reperfusion.  
 
2 IS LOSS OF PHD1 NEUROPROTECTIVE VIA EXTRINSIC (VASCULAR) 
MECHANISMS OR BY MODULATING INTRINSIC (NEURONAL) FEATURES?  
By promoting blood supply or by modulating the intrinsic resilience of cells 
against hypoxia and oxidative stress, PHDs are the master regulators of the 
adaptive response to hypoxic stress. Stroke outcome has extensively been 
linked to the extent of residual perfusion, which is determined by the degree 
of collateral circulation (Shuaib et al 2011). Upon acute occlusion of the 
middle cerebral artery, pial collateral vessels can, via retrograde filling, still 
supply brain regions distal to the occlusion, alleviating the drop in perfusion 
(Brozici et al 2003). Studies in both experimental models (Chalothorn and 
Faber 2010, Defazio et al 2011, Zhang et al 2010) and patients (Bang et al 
2008, Kucinski et al 2003, Lima et al 2010, Maas et al 2009, Miteff et al 2009, 
Shuaib et al 2011) pinpointed the collateral circulation as an important 
determinant of stroke size and outcome.  
PHDs have been previously linked to arteriogenic remodeling and 
improved collateral flow (Takeda et al 2011). Also, chronic cerebral hypoxia 
was recently shown to promote arteriogenesis in the brain (Boroujerdi et al 
	   108 
2012, Freitas-Andrade et al 2012). We did not observe any effect of PHD1 
deficiency on the number of pial collaterals (responsible for the residual 
perfusion in experimental MCAO models (Zhang et al 2010)). Also, neither 
vessel perfusion nor arterioles were affected in the PHD1-/- brain. All these 
vascular parameters were assessed in non-stroked animals, since a possible 
contribution of vascular preconditioning would imply them to be altered prior 
to the occlusion. The lack of a clear vascular phenotype in the PHD1-/- brains 
is compatible with the findings in other PHD1 deficient organs, where vascular 
effects have never been described either (Aragones et al 2008, Schneider et al 
2009). In line with our data, a single study assessing vessel density in the 
PHD1-/- brain, did not report any difference either (Chen et al 2012).  
Rather, our data indicate that a cell-autonomous neuronal mechanism 
contributes to the increased resistance of the PHD1-/- brain against brain 
ischemia. Neuronal cultures lacking PHD1 were indeed protected against 
ischemia (i.e. deprivation of oxygen and nutrients) as well, indicating that 
PHD1 deficiency affects intrinsic neuronal properties that increase their 
ischemic resilience.  
Our ongoing studies show that PHD1-/- neurons were not only 
protected against ischemia but also against glutamate excitotoxicity (data not 
shown). Excitotoxicity refers to the pathological overactivation of NMDA-
receptors by glutamate. In ischemic conditions extracellular glutamate levels 
rise due to the rundown of ion gradients and ATP depletion (Hertz 2008). 
Excitotoxicity is one the main mechanisms contributing to neuronal ischemic 
death both in vitro and in vivo (Hertz 2008). Pilot experiments showed that the 
protection of PHD1-deficient neurons against excitotoxicity was not due to 
different levels or calcium-conducting properties of NMDA-receptors, nor due 
to altered expression of glutamate reuptake transporters. Also, we did not 
observe genotypic differences in expression levels of a variety of neurotrophin 
genes, which are known to increase neuronal survival in conditions of 
ischemia and excitotoxicity (Almeida et al 2005, Brandoli et al 1998, Ferenz et 
al 2012, Klumpp et al 2006). 
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3 METABOLIC REWIRING IN PHD1 DEFICIENT NEURONS 
PHDs are considered as integrators and orchestrators of cellular metabolism. 
Most of the known metabolic effects of reduced PHD activity are HIF-
dependent and aim to reduce oxygen consumption and energy expenditure 
(see also figure 5 in chapter I). In the context of ischemia, these HIF-mediated 
metabolic changes have been mainly considered as a means of oxygen-
independent energy generation. Also in the brain and in cultured neurons, 
aspecific PHD inhibitors as well as PHD2 deletion were shown to induce the 
transcription of glycolytic genes (Baranova et al 2007, Kunze et al 2012, 
Zaman et al 1999). However, without demonstrating any functional or 
biological significance, these studies leave the link between PHDs and cellular 
metabolism in the brain largely enigmatic. Here, we uncovered a novel 
metabolic reprogramming in PHD1-/- neurons, as summarized in figure 21. 
Many novel insights and intriguing questions come forth from these findings 
as detailed in the next paragraphs. 
 
3.1 PHD1 deficiency in neurons does not phenocopy the metabolic 
phenotype in the PHD1-/- muscle 
First of all, these findings implicate that the metabolic features of PHD1-/- 
neurons do not mimic the metabolic phenotype in the ischemia tolerant PHD1-
/- muscle (Figure 21). PHD1-/- muscle fibers showed a striking reduction in 
oxygen consumption in combination with an enhanced glycolytic flux and 
lactate production (Aragones et al 2008). Conversely, oxygen consumption 
was not affected in PHD1-/- neurons and, instead of an increase in glycolysis, 
they rather showed a modest reduction in their glycolytic flux. This finding 
was rather surprising given the overwhelming evidence that HIF-α stabilization 
promotes the glycolytic flux via transcriptional activation of several glycolytic 
genes (Schneider et al 2009). In contrast, a decrease in glycolysis was 
recently described in PHD3 deficient fibroblasts, which was attributed to the 
lack of hydroxylation and degradation of the glycolytic enzyme PKM2 (Luo et 
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al 2011). A possible direct interaction between PHD1 and PKM2 remains 
elusive. We also discovered that neuronal PHD1 deficiency increased the flux 
through the oxPPP. To the best of my knowledge, this is the first study to 
show a link between PHDs and the oxPPP. It is unclear at the moment 
whether this is a cell type-specific effect limited to neurons. Of note, in 
absolute terms the decrease in glucose flux through glycolysis is more 
pronounced than the increase in PPP flux.  
 
Figure 21: Comparison of metabolic rewiring in PHD1-/- muscle fibers 
versus PHD1-/- neurons. 
The left panel shows a schematic overview of the metabolic changes in the 
PHD1-/- muscle fibers. Entry of pyruvate in the mitochondria is reduced. As a 
consequence, less oxygen is consumed and less ROS are generated in the 
mitochondria (OXPHOSPH: oxidative phosphorylation). Glycolytic flux and 
lactate excretion are increased. The right panel summarizes the metabolic 
alterations in the PHD1-/- neurons. Glucose is shifted away from glycolysis into 
the PPP. Due to reduced entry of glycolytic intermediates in the mitochondria, 
glucose oxidation is reduced. Oxygen consumption and ATP production are 
however similar due to the increased oxidation of glutamine. For reasons of 
simplicity and clarity, the stoichiometry of the reactions has been omitted. 
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A link between PHDs and glycogen metabolism has been suggested by 
the observation that hypoxia induces the expression of the enzymes 
responsible for glycogen degradation and synthesis (glycogen phosphorylase 
and glycogen synthase respectively) (Favaro et al 2012). Complementary 
studies in the host laboratory showed that loss of PHD1 increased glycogen 
accumulation in the liver. Nevertheless, the preliminary observation that 
PHD1-/- neurons show a higher glycogen content was rather unexpected, 
given the common belief that neurons cannot store glycogen (DiNuzzo et al 
2011). 
 
3.2 PHD1 deficiency has cell-type specific molecular mediators 
Another interesting insight coming forth from these studies is that PHD1 
deficiency, besides inducing different metabolic phenotypes, also has cell-
type specific molecular mediators. In the PHD1-/- muscle, ischemia tolerance 
was at least partially attributed to HIF-2α (Aragones et al 2008). In PHD1-/- 
neurons however, HIF-1α levels were not affected and HIF-2α could not be 
detected. In addition, silencing of HIF-2α or HIF-1α failed to affect the 
ischemic protection in PHD1-/- neurons. A recent study did not observe HIF-
1α accumulation in the PHD1-/- brain either (Chen et al 2012). Instead, pilot 
experiments showed that PHD1-/- neurons have enhanced NF-κB activity with 
increased protein levels of p65 and c-Rel, two members of the NF-κB 
transcription factor family (data not shown). HIF-independent targets of the 
PHDs are increasingly being recognized and probably, we know merely a 
small fraction of them. Interesting in this regard is that during evolution, PHDs 
arose earlier than HIFs (Place et al 2011). Nevertheless, in the brain, the 
literature on the protective effects of PHD inhibition is primarily HIF-1α 
focused (Nagel et al 2010, Quaegebeur and Carmeliet 2010). An intriguing 
finding is that our in vitro ischemia data might even point to an antagonistic 
role of HIF-1α, in line with an earlier study reporting a beneficial effect of HIF-
1α silencing in an assay of neuronal oxidative death (Siddiq et al 2009). Still, 
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the in vivo significance of HIF-1α and HIF-2α in stroke needs further 
investigation.  
 	  
4 HOW WOULD ENHANCED OXPPP FLUX AND GLYCOGEN 
ACCUMULATION IN NEURONS PROTECT AGAINST ISCHEMIA? 
Based on our findings, we propose the following mechanisms to explain the 
neuroprotective effect of PHD1 loss (Figure 22): 
 
Figure 22: Model of preserved redox and energy homeostasis in the 
PHD1-/- neurons during ischemia 
PHD1 deficiency in neurons shunts glucose from glycolysis into the PPP. Via 
increased NADPH generation, this will accelerate the glutathione recycling, 
improving redox homeostasis in conditions such as neuronal ischemia. The 
increased glycogen accumulation might additionally prevent an energetic crisis 
as an alternative and more efficient energy fuel for ATP generation during 
ischemia.  
 
4.1 Enhanced oxPPP flux ensures redox homeostasis 
In our study, we described for the first time that PHD1-/- neurons shunt more 
glucose through the oxPPP as compared to wild type neurons. In this way, 
they generate more of the reducing equivalent NADPH to replenish the pool of 
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reduced glutathione. This increase in oxPPP flux was associated with a 
decrease in glycolytic flux, raising the possibility that the regulation of this 
metabolic shift is at the level of the glycolysis/PPP crossroad. The increased 
oxPPP flux and consequently accelerated recycling of reduced glutathione 
enabled PHD1-/- neurons to detoxify H2O2 at a higher rate. Indeed, we 
observed an improved scavenging capacity of H2O2 in PHD1
-/- neurons, which 
was negatively affected upon oxPPP blockade.  
Given the widely held notion that oxidative stress in brain ischemia is 
heavily intertwined in the pathological cascade of events that leads to 
neuronal death (Chan 2001, Moskowitz et al 2010), the increase in PPP flux is 
likely to confer protection in this context. Some supporting evidence for this 
model exists in the literature, even though the role of the PPP in the brain 
remains understudied and even controversial. The NADPH molecules 
generated in the PPP appear to have opposing fates. As a reducing co-factor 
of glutathione reductase, NADPH will improve the anti-oxidant capacity, 
whereas as a cofactor of NADPH oxidase, it will promote superoxide 
generation (Stanton 2012). NADPH oxidase is a multi-subunit enzyme 
complex in the membrane that when activated generates superoxides by 
using NADPH as an electron donor (Bedard and Krause 2007). While this 
activity has been well described in activated neutrophils, its relevance in 
neurons is debated (Bedard and Krause 2007).  
This intriguing conundrum of both ROS promoting and ROS reducing 
effects of the PPP is so far not well understood and probably explains the 
diverging reported results on the role of PPP in neurons. Flux through the 
oxPPP was found to be crucial for neuronal anti-oxidant defense, since 
PFKFB3 overexpression, which withdraws glucose from the PPP, resulted in 
oxidative death (Herrero-Mendez et al 2009). The same group also discovered 
that excitotoxicity impaired proteasomal degradation of PFKFB3, thereby 
reducing the PPP flux, whereas PFKFB3 silencing in these conditions was 
protective (Rodriguez-Rodriguez et al 2012). Conversely, other studies 
suggested that PPP powers NADPH oxidase activity in ischemia and 
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excitotoxicity (Brennan et al 2009, Suh et al 2008). On another note, the PPP 
flux could also fuel nucleotide synthesis via the generation of ribose-5-
phosphate (Stanton 2012), which could facilitate DNA repair of the 
accumulating oxidative DNA damage. 
The role of PPP in stroke specifically has been little studied. One study 
assessed the effect of silencing glucose-6-phosphate-dehydrogenase (G6PD, 
the rate-limiting enzyme of the PPP). This was found to reduce infarct size 
when silenced at the onset of stroke (probably by inhibition of NADPH 
oxidase activity) whereas at a later stage, inhibition of the PPP flux 
aggravated stroke outcome (Zhao et al 2012). Recently, levels of Tp53-
Induced Glycolysis and Apoptosis regulator (TIGAR) were found to determine 
stroke size (Li et al 2014). TIGAR is a bisphosphatase that inhibits the activity 
of PFK-1 and thereby favors glucose utilization by the oxPPP flux at the 
expense of glycolysis. Therefore, the protective effect of TIGAR 
overexpression in stroke could possibly be attributed to an enhanced PPP 
flux. Still, since other functions of TIGAR are being increasingly recognized 
(Gerin et al 2014), the causality of this finding requires further research. 
Notably, our data do not exclude that PHD1-/- neurons activate other 
pathways besides the oxPPP that might contribute to their improved ROS 
scavenging capacity. Possible candidates in this regard might be the 
mitochondrial NADPH generating enzymes such as malic enzyme, isocitrate 
dehydrogenase and nucleotide nicotinamide transhydrogenase (Arkblad et al 
2002, Minich et al 2003, Vogel et al 1998) as well as the recently described 
folate-dependent NADPH production by methylenetetrahydrofolate 
dehydrogenase (Fan et al 2014, Lewis et al 2014). Another puzzling question 
is how the oxidative PPP flux in the cytosol can contribute to ROS scavenging 
in the mitochondria, putatively the main ROS generating site during ischemia. 
Different possible NADPH shuttles between the cytosol and the mitochondria 
can be put forward, yet, their contribution needs further investigation. Of 
interest, PFKFB3 inhibition is believed to protect against excitotoxicity via an 
increase of the PPP flux (Rodriguez-Rodriguez et al 2012). 
	   115 
 
4.2 COUNTERACTING THE HYPOXIC OXPPP à  GLYCOLYSIS SHIFT  
In most cells, hypoxia will via HIF-1α shift energy metabolism from 
mitochondrial respiration towards anaerobic glycolysis, which pursues 
oxygen-independent energy production. We showed that also neurons 
respond to hypoxia by promoting their glycolytic flux, in accordance with the 
existing literature (Malthankar-Phatak et al 2008). Many reasons can be put 
forward that would explain the potential benefit of these metabolic changes 
(reduction of mitochondrial ROS production, energy compensation by 
glycolytic ATP, etc.). Still, this study might provide a clue as to why neurons 
are so vulnerable to ischemia despite this metabolic adaptation. We observed 
that the increased glycolysis in hypoxic neurons was associated with a 
complete disappearance of the flux through the oxPPP. This finding 
corroborates the idea of a reciprocal regulation of the oxPPP/glycolysis 
balance and lets us speculate whether hypoxia would augment PFKFB3 
protein levels that withdraw glucose from the PPP flux. Interestingly, both in 
cell culture and animal models of neurodegenerative disorders signs of 
increased glycolysis have been described as well (D'Alessandro et al 2011, 
Ferreira et al 2011, Yao et al 2009), raising the question whether also here a 
similar detrimental metabolic shift is taking place, depleting neurons from their 
vitally important PPP flux. PPP flux alterations in neurodegenerative disorders 
have not been studied so far. 
PHD1 deficiency will not only promote oxPPP flux in baseline – 
normoxic – conditions. Our observation that PHD1-/- neurons maintain a 
residual PPP flux during hypoxia is likely to be even more relevant for their 
hypoxia tolerance, as at that time redox homeostasis will be acutely 
threatened. At the same moment, glycolysis levels in PHD1-/- neurons do not 
reach the same level as in their wild type counterparts. Taken together, these 
data indicate that the expected hypoxia-induced metabolic reprogramming is 
attenuated by PHD1 deficiency. This would implicate that loss of PHD1, by 
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counteracting the HIF-mediated metabolic changes, would enable redox 
control in hypoxic conditions.  
 
 
Figure 23: Model on effect of PHD1 deficiency on glycolysis/PPP balance 
in conditions of neuronal injury 
Many conditions of neuronal injury such as excitotoxicity, ischemia and 
neurodegeneration are associated with an increased glycolysis. Excitotoxicity 
was previously shown to reduce PPP, and in this study we show that hypoxia 
nullifies the flux through the PPP. This metabolic shift from PPP towards 
glycolysis is likely to adversely affect neuronal survival, as these changes will 
deplete neurons from their major anti-oxidant mechanism. We postulate that 
PHD1 deficiency enacts a neuroprotective effect by shunting glucose back 
from glycolysis into the PPP, thereby restoring the balance between glycolysis 
and the oxPPP. 
 
 
4.3 GLYCOGEN STORES AS AN ALTERNATIVE ENERGY SOURCE 
POTENTIALLY CONTRIBUTE TO ENERGY HOMEOSTASIS 
Our preliminary observation that PHD1-/- neurons stored more glycogen was 
rather surprising given the existing view on glycogen in the brain. Glycogen 
storage in the brain has been assumed to be an astrocyte-specific process 
(Brown and Ransom 2014). The common belief is that neurons are not able to 
store glycogen and that neuronal glycogen accumulation might even be 
deleterious (DiNuzzo et al 2011). It was only very recently that a small pool of 
glycogen in neurons was recognized to be important for energy generation in 
ischemic conditions (Saez et al 2014). Although increased glycogen content in 
ISCHEMIA/NEURONAL INJURY
PPP
glycolysis
PHD1 DEFICIENCY
PPPglycolysis
	   117 
PHD1-/- neurons could readily explain their preserved energy charge during 
prolonged oxygen nutrient starvation in vitro, its relative contribution and in 
vivo relevance will have to be demonstrated. Of note, in contrast to the ATP 
consuming process of glucose uptake, degradation of glycogen into glycolytic 
intermediates is energetically more favorable and might therefore be provide 
an additional energy-saving advantage in hypoxia. 
 
 
4.4 RELEVANCE OF ENHANCED GLUTAMINE OXIDATION? 
In baseline conditions (i.e normoxia), the increased ATP production through 
the enhanced glutamine oxidation likely compensates for the decrease in ATP 
production from the reduction in glucose oxidation. It is however less clear 
whether the increased preference for glutamine as oxidative substrate would 
contribute to the ischemic protection. From an energetic standpoint, low 
oxygen availability in ischemic conditions would limit oxidative metabolism 
and hence prevent glutamine’s contribution to energy production. However, 
oxygen tension in the mitochondria will only become limiting in nearly anoxic 
conditions (Semenza 2012). Still, the role of glutamine in brain ischemia 
remains obscure, which likely relates to the different fates of glutamine in 
neurons: besides energy purposes through mitochondrial oxidation, glutamine 
also serves as precursor for the neurotransmitter glutamate and as precursor 
for the anti-oxidant glutathione (McKenna 2007). There are reports showing 
that the presence of glutamine in the medium in conditions of mitochondrial 
dysfunction even aggravates neuronal cell death (Goldberg et al 1988, 
Stelmashook et al 2007, Stelmashook et al 2010). This is likely due to 
enhanced production of glutamate, facilitating excitotoxicity. 
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5 IS PHD1 INHIBITION ALSO PROTECTIVE IN NEURODEGENERATIVE 
DISORDERS? 
Acute ischemic stroke might be the most striking example of acute 
deregulated oxygen homeostasis. Still, many other brain diseases are also 
characterized by metabolic and vascular deficits (Quaegebeur and Carmeliet 
2010, Quaegebeur et al 2011). Amyotrophic lateral sclerosis is a 
neurodegenerative disorder characterized by the progressive dysfunction and 
death of motorneurons resulting in paralysis, muscle atrophy and ultimately 
death of the patient (Van Damme and Robberecht 2014). Many pathogenetic 
mechanisms have been implicated in this heterogeneous disease among 
which hypoxic and oxidative stress, rationalizing the study of PHD1 deficiency 
in this disorder (Quaegebeur and Carmeliet 2010). We discovered a beneficial 
effect of genetic PHD1 knockdown in the SOD1G93A model on survival and 
onset of paralysis. Whether metabolic alterations in motorneurons are 
responsible for attenuating motor neuron death requires further research. 
Whether PHD1 deficiency would be beneficial in other neurodegenerative 
disease such as Alzheimer’s and Parkinson’s disease remains an outstanding 
question as well.  
 	  
6 IS PHD1 INHIBITION A VALID THERAPEUTIC APPROACH IN STROKE? 
We showed that silencing of PHD1 in the brain via intracerebroventricular 
delivery of antisense oligonucleotides protects against brain ischemia. This 
study is to the best of my knowledge the first study where pharmacological 
inhibition of a specific PHD isoform in stroke was investigated. The existing 
PHD inhibitors with proven benefit in experimental stroke studies carry major 
disadvantages for their clinical translation. Their lack of specificity for PHD 
proteins gives rise to an unfavorable side-effect profile preventing them to 
become a valid reagent for assessment in clinical trials (Fraisl et al 2009). 
Therefore, our therapeutic success with PHD1 inhibition reflects an important 
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proof of concept in the therapeutic assessment of PHD inhibitors in stroke 
and rationalizes a continued search for PHD-isoform specific inhibitors. 
In this study, silencing of PHD1 was initiated prior to stroke induction. 
This implicates PHD1 inhibition as a preconditioning strategy. In cerebral 
preconditioning, the brain is exposed to a controlled stressful stimulus, such 
as transient ischemia, to an extent that neuronal function is slightly impaired, 
yet not irreversibly damaged. It has been extensively described that this will 
elicit a protective response, attenuating brain damage following a more severe 
stressor (Quaegebeur and Carmeliet 2010). PHD1 inhibition might be one of 
the underlying molecular mechanisms of cerebral preconditioning: by 
installing metabolic changes, PHD1 deficiency would prepare the brain in 
advance to cope with a future drop in oxygen supply. In that respect, PHD1 
inhibition would be clinically useful in situations where the risk of cerebral 
ischemia is considered high such as upon a critical arterial stenosis (e.g. high 
grade carotid stenose, intracranial atherosclerosis, Moyamoya disease) or 
following a subarachnoid hemorrhage.  
What about using PHD1 inhibition as a neuroprotective strategy after 
stroke? Beneficial effects within the neuroprotective window would implicate 
that PHD1 inhibition is not only able to prime brain tissue for ischemia, but 
also able to interfere with the ongoing series of detrimental events in the 
ischemic cascade. Based on different studies in humans, the therapeutic time 
window is likely to be rather short (within hours after stroke onset) (Tymianski 
2013). Yet, in hemorrhagic stroke where via expansion of the hematoma the 
tissue might suffer from secondary ischemia, the therapeutic window might 
be longer. Some studies have reported beneficial effects with post-stroke 
administration of PHD inhibitors (Nagel et al 2011, Ogle et al 2012, Reischl et 
al 2014). Whether PHD1 inhibition will have a clinically relevant therapeutic 
time window will need further investigation. 
As a final critical note, one could wonder why PHD1 inhibition would be 
effective as a stroke treatment whereas so far, neuroprotective drugs 
targeting oxygen radicals and excitotoxicity have repeatedly failed in clinical 
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trials (Ginsberg 2008). Many reasons can be put forward to explain this 
translational failure both at the clinical and the preclinical level. It has become 
clear that the ischemic cascade involves a complex interplay between 
deleterious processes, so that targeting one mechanism such as oxygen 
radicals or excitotoxicity is unlikely to have major effects (Ginsberg 2009). In 
addition, many stroke treatments have neglected the delicate and complex 
biology of oxygen radicals and NMDA-receptor signaling. Even though 
excesses of these are toxic, they both fulfill essential physiological signaling 
functions in neurons (Moskowitz et al 2010). Therapeutics should therefore be 
focused on attenuating the excessive effects rather than simply blocking 
either of them. PHD1 inhibition is in this regard an interesting approach since 
it appeals to an endogenous protective mechanism with pleiotropic actions. 
As for the clinical trials, without going into detail on their methodological 
issues that likely contributed to the translational difficulties, it will be crucial 
for strategies such as PHD1 inhibition to select an appropriate patient 
population and to hold on to a strict time window (Moskowitz et al 2013).  
 
 
7 CONCLUSIONS AND FUTURE PERSPECTIVES 
Our study revealed that PHD1 is a valid therapeutic target in stroke and 
extended our insights into the role of PHD1 as a metabolic regulator. Neurons 
lacking PHD1 shift their glucose from glycolysis towards the PPP, thereby 
enhancing their anti-oxidant potential. Initial data also point to increased 
glycogen accumulation providing an alternative energy source during 
ischemia. Whether this metabolic rewiring in neuronal cultures is relevant for 
the protection against ischemia in vivo is the topic of further research. 
Additionally, this study represents a proof of concept that pharmacological 
inhibition of a specific PHD isoform governs neuroprotection in ischemic 
stroke. 
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Chapter VI  
 
SUMMARY 
 
 
The brain relies on a continuous supply of oxygen and nutrients. In ischemic 
stroke, an abrupt arterial occlusion results in oxygen and nutrient deprivation 
within the perfusion area of the affected vessel. As the second leading cause 
of death and the most common reason for severe disability, the medical, 
social and economic impact of stroke can hardly be overstated.  
Below a certain threshold of blood flow reduction, neurons will undergo 
necrotic death due to complete bioenergetic failure. Surrounding this 
irreversibly lost tissue, there is a region that suffers moderate blood flow 
reduction. This ischemic penumbra is still viable and hence salvageable 
during a certain time window. A cascade of deleterious events will disrupt 
energy and redox homeostasis and result in ischemic death unless perfusion 
is restored via recanalization or if a neuroprotective drug interferes with this 
downward spiral. 
Given the vital importance of maintaining oxygen and metabolic 
homeostasis, mammalian organisms are equipped with oxygen sensing 
mechanisms among which the Prolyl Hydroxylase Domain proteins (PHDs). 
PHDs are a class of oxygen sensors inducing adaptive processes to restore 
oxygen homeostasis in an oxygen-dependent manner. In hypoxia, PHDs lose 
their hydroxylation activity and thus activate a major transcriptional pathway 
governed by the hypoxia-inducible factors (HIFs). There are 3 different PHD 
isoforms (PHD1,2,3) and only during recent years their non-redundant and 
tissue-specific functions are being unraveled. The host lab previously 
documented that absence of PHD1 provided ischemia tolerance to muscle 
and liver cells through a metabolic reprogramming that switches from 
mitochondrial respiration to anaerobic glycolysis.  
Aspecific PHD inhibitors were shown to be neuroprotective in acute 
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neurotoxic settings such as stroke, but their lack in specificity prevents 
translation into the clinical setting and any insight into the underlying 
mechanisms. These aspecific inhibitors have been linked to an increase in 
glycolysis, but whether this is responsible for the neuroprotective effect is 
unresolved. Remarkably, the precise role of metabolic alterations in the 
pathogenesis of neuronal injury as well as their significance in neuroprotection 
remains largely obscure. This doctoral work aimed to characterize the role of 
PHDs in ischemic stroke and to better understand the underlying molecular 
and cellular underpinnings of their effects.  
We showed that deletion of oxygen sensor PHD1 largely prevented 
brain ischemia after ligation of the middle cerebral artery. We uncovered a 
novel metabolic rewiring in PHD1 deficient neurons that was strikingly 
different from the metabolic phenotype in the PHD1 deficient muscle. 
Neurons lacking PHD1 shunted more glucose into the oxidative pentose-
phosphate pathway (oxPPP). The oxPPP represents an alternative route for 
glucose besides glycolysis, critical for redox homeostasis by generating 
NADPH, which is necessary to replenish reduced glutathione. In line with 
these findings, the capacity to scavenge oxygen radicals was improved in 
neurons lacking PHD1. Contrary to wild type neurons, PHD1 deficiency also 
enabled a residual flux through the oxPPP during hypoxia. In this way, PHD1 
deficient neurons have an increased tolerability towards the surge in oxygen 
radicals during ischemia. Finally, silencing of PHD1 by intracerebroventricular 
delivery of antisense oligonucleotides was protective against brain ischemia. 
These findings not only identify a novel therapeutic target for ischemic stroke 
but also provide novel insights into the link between oxygen sensors, 
metabolism and neuroprotection.  
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SAMENVATTING 
 
Hersenen hebben nood aan een continue toevoer van zuurstof en 
voedingsstoffen. Bij een beroerte zal een acute slagaderverstopping leiden tot 
een tekort aan zuurstof en voedingsstoffen in het gebied dat het verstopt 
bloedvat voorziet. Beroertes zijn momenteel de tweede doodsoorzaak en de 
belangrijkste oorzaak van zorgbehoevendheid. De medische, sociale en 
economische impact van beroertes kan dus moeilijk overschat worden.  
Wanneer de bloedtoevoer onder een bepaalde drempel zakt, zal dit 
onmiddellijk tot necrose van neuronen leiden door een volledig energetisch 
falen. Rond deze kern van onomkeerbaar verloren weefsel is er een regio 
waar de bloedvoorziening slechts matig gedaald is. Omdat deze “ischemische 
penumbra” nog gedurende een bepaald tijdsvenster viabel is, kan deze nog 
gered worden. In dit gebied zal een reeks van schadelijke gebeurtenissen de 
energie en redox homeostase verstoren en uiteindelijk aanleiding geven tot 
celdood, tenzij dat recanalisatie de bloeddoorstroming herstelt of dat een 
neuroprotectief medicijn interfereert met deze neerwaartse spiraal.  
Aangezien het onderhouden van een zuurstof- en metabool evenwicht 
van crucial belang is, zijn zoogdieren uitgerust met zuurstofsensor 
mechanismen waaronder de Prolyl Hydroxylase Domein proteïnen (PHDs). 
PHDs zijn een klasse van zuurstofsensoren die op een zuurstof-afhankelijke 
manier aanpassingsmechanismen activeren om het zuurstofevenwicht te 
herstellen. In hypoxie zullen PHDs hun hydroxylatie activiteit verliezen en zo 
een belangrijk transcriptie-programma activeren via de hypoxie-induceerbare 
factoren (HIFs). Er zijn drie verschillende PHD isovormen (PHD1, 2,3) en het is 
enkel gedurende de laatste jaren dat we hun niet-overlappende en weefsel-
specifieke functies leren kennen. Het gastlaboratorium heeft in het verleden 
aangetoond dat de afwezigheid van PHD1 de spier en de lever resistent 
maakte aan ischemie en dit door een metabole reprogrammering waarbij 
mitochondriale respiratie werd ingeruild voor glycolyse.  
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Experimenteel onderzoek toonde reeds aan dat aspecifieke PHD 
inhibitoren neuroprotectief werken in acute neurotoxische settings zoals 
beroertes. Hun gebrek aan specificiteit bemoeilijkt echter de vertaling naar 
een klinische context en levert ook geen enkel inzicht in het onderliggend 
mechanisme. Deze aspecifieke inhibitoren werden geassocieerd aan een 
toegenomen glycolyse, maar het blijft onbekend in hoeverre dit 
verantwoordelijk is voor het neuroprotectief effect. Opmerkelijk is dat de 
precieze rol van metabole veranderingen in het ontstaan van neuronale 
schade alsook hun bijdrage in neuroprotectie grotendeels ongekend blijft. 
Deze doctoraatsthesis beoogde om de rol van de PHDs in beroertes te 
karakteriseren en om de onderliggende moleculaire en cellulaire 
mechanismen van hun effecten beter te begrijpen.  
We hebben aangetoond dat deletie van de zuurstofsensor PHD1 
grotendeels beschermt tegen hersenischemie na het afbinden van de 
middelste cerebrale arterie. We ontdekten een ongekende metabole 
reprogrammering in neuronen zonder PHD1 die opmerkelijk verschillend was 
van de metabole veranderingen in de PHD1-deficiënte spier. Neuronen 
zonder PHD1 stuurden meer glucose in de oxidatieve pentose fosfaat 
cascade. Via deze alternatieve route voor glucose wordt er NADPH 
aangemaakt dat noodzakelijk is voor het regenereren van gereduceerd 
glutathion, een belangrijk anti-oxidant in neuronen. In de lijn van deze 
bevindingen was de capaciteit om zuurstofradicalen te neutraliseren ook 
hoger in neuronen zonder PHD1. In tegenstelling tot wild type neuronen 
zorgde de afwezigheid van PHD1 voor een residuele flux door de pentose 
fosfaat cascade tijdens hypoxie. Op deze manier zijn PHD1-deficiënte 
neuronen beschermd tegen de stijging van zuurstofradicalen tijdens ischemie. 
Tenslotte, het verminderen van PHD1 door intracerebroventriculaire 
toediening van oligonucleotides beschermde ook tegen hersenischemie. Deze 
bevindingen identificeren niet enkel een nieuw therapeutisch doelwit voor 
ischemische beroertes, maar verschaffen ook nieuwe inzichten in de link 
tussen zuurstofsensoren, metabolisme en neuroprotectie. 
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Eibsee meeting (Münich, Germany, November 2012) 
• Quaegebeur A. Oxygen sensors, neuroprotection and metabolism: 
unexpected liaisons and therapeutic opportunities for neurodegeneration? 
Lecture at Department of Molecular and Developmental Genetics (VIB, 
K.U.Leuven, Belgium, September 2012) 
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• Quaegebeur A & Carmeliet P. Bloedvaten en stofwisseling: waarom 
zuurstof belangrijk is in ALS. ALS liga symposium (UZ Leuven, Belgium, 
October 2010) 
 
AWARDS & FELLOWSHIPS 
• FWO PhD fellowship 2009 - 2013 
• Junior Investigator International Travel Award for the 10th International 
Conference for Brain Energy Metabolism  (April 2012) 
• Fonds “A Cure for ALS”. PHD1 as novel neuroprotective target in ALS 
(December 2012) 
 
 
